



LOTUS EYE HOSPITAL & INSTITUTE



28th
ANNUAL
REPORT
2024-2025



Late Dr. S. K. SUNDARAMOORTHY

(21.08.1944 - 22.01.2020)

“There are some who bring a light so great to the world that even after they have gone the light remains”

Our founder Dr. S.K. Sundaramoorthy was one of the acclaimed and famed eye surgeons of our country and worldwide. He obtained his MBBS degree from Stanley Medical College, Chennai in 1971, completed M S (Opthal) in Madurai Medical College in 1980. Fellowship programme in Retinal surgery in Sankara Netralaya, Chennai (1980-1982) and obtained twin super specialty degrees namely FRCS (Edin) and FRCO (Lon).

“LOTUS” is the Magnus opus of his legendary vision, determination and pure hard-work. We at LOTUS are relentless in carry forwarding his legacy forever through the quality and stakeholder satisfaction that we are known for.

The legacy of Dr. S.K. Sundaramoorthy is incomparable and exceptional, where in, the values are steeped well into the very roots of the foundations of this great institution. The management behind the brand ‘LOTUS’ are cognizant of the illustrious and celebrated purpose for this institution, striving to achieve and surpass the same



INDEX

Company Overview		: 02 - 06
Chairman's Message		: 07
Managing Director Message		: 08
Corporate Information		: 09 -12
Notice to shareholders		: 13 - 27
Director's Report		: 28 - 40
Corporate Governance Report		: 41 – 61
Management Discussion Analysis Report		: 62 - 65
Secretarial Audit report		: 66 - 71
Independent Auditors Report		: 72 - 98
Financial Statements		: 99 - 107
Notes to Financial Statements		: 108 - 136



CORPORATE STATEMENT

Service oriented approach is the motto of the organization. Lotus Eye Hospital and Institute Limited has been chiseled to meet the aspirations of all its stakeholders. Each and every decision of the companies reckons the effect of it in our stakeholders. The larger idea is to serve the population by providing the most advanced and viable eye care services.

Our paramount goal is to provide the best and advanced eye care services to the larger population. The journey of lotus since its inception from 1997 is a testimony of the fact that we are committed towards achieving our goal. In order to attain our goal we have with us a vibrant and dedicated medical team which considers providing best eye care services as their mission. The idea of serving the masses is the greatest motivation of lotus and this goal helps in pushing us to explore uncharted business environment and disseminate the best services possible. Our stakeholders are the greatest strength who has always reposed the utmost faith in our brand lotus. We will strive more to cater to the needs of the stakeholders in all our endeavor's

COMPANY PROFILE

Lotus Eye Hospital is a hi-tech super specialty eye care hospital catering its value added service to the society since inception. Lotus is known for its excellence in Ophthalmic service with personalized care. This organization is committedly pioneering in the technological revolution in eye care and rendering service to thousands of patients from across the globe to see the world better than ever before.

- **Founded in 1990** by renowned ophthalmic surgeon late **Dr. S.K. Sundaramoorthy**
- Lotus Eye Hospitals operates **9 Eye Care centers** in Tamil Nadu and Kerala
 - ✓ **7 Centres in Tamil Nadu:** Coimbatore (Peelamedu , RS puram and Saravanampatti), Salem , Tirupur Mettupalayam and Karur
 - ✓ **2 Centres in Kerala:** Kochi and Mulanthuruthy
- Listed at NSE and BSE in 2008; current **market capitalization of more than INR 150 Crores***

300+

2 Lakh+

10 Lakh+

1 Crore+

Qualified Staff's

Surgeries

Procedures

Eyes Screened



Vision


To become world's leading eye care provider with happy and satisfied patients and stake holders.

Lotus has a vision of "empowering eyes to illuminate lives". Lotus Eye Care group is marching towards its vision of becoming India's best Corporate Hospital with branches in strategic locations where quality eye care is in need, and render world class eye care service to the society.

Mission

- To be the center of excellence in India by providing quality eye care of highest levels with skill competence and concern.
- To be adopting latest technologies, techniques and ethical practice in ophthalmology.
- To be setting up basic and clinical research into eye diseases and vision threatening conditions.
- To be focusing on Education, Training, Product Development and rehabilitation for incurable diseases.
- To be a preferred center for eye care Professionals, Para-medical and Non-medical team.

VALUES



Wide Range of Services



Refractive

- LASIK/ BladelessLASIK
- Zyoptix & Zyoptix Ultimate
- Epizyoptix & Epizyoptix Ultimate
- SMILE
- Paediatric refraction and Special Kertometer
- Synaptophore
- Lasik for Anisometropia correction for different image size and Amblyopia



Cornea

- Cataract Surgery
 - ✓ SICS
 - ✓ Phaco
 - ✓ MICS
 - ✓ LRCS
 - ✓ SF IOL
- Corneal Patch graft
- Corneal Scleral Repair
- Corneal Scrapping +AMG
- Corneal Suture
- Corneal Tatooing
- Corneal Tear Suturing
- Cortical Drop Removal
- Pertygium Exc. With AG
- C3R
- Penetrating Keratoplasty (PKP)
- TPK & DALK
- DASE



Retina

- Vitrectomy
 - Membrane Peeling
 - Endolaser
- ERM Removal
- Silicon Oil & Removal
- Vitrectomy Lavage
- FGE & C3F8
- LPFC & CYCLO CRYO
- Scleral Buckling & Belt Buckle
- Injections
 - ✓ Inj. Ivta
 - ✓ Inj. Avastin
 - ✓ Inj. Razumab
 - ✓ Inj. Ozurdex
 - ✓ Inj. Zybev
 - ✓ Inj. Eyelea
 - ✓ Inj. Lucentis
 - ✓ Inj. Accentrix



Glaucoma

- Trabeculectomy



Oculoplasty

- Enucleation
- Evisceration
- DCR & DCT
- PTOSIS
- Lateral Tarsorrhaphy

Milestones

- ❖ 1989 - Opening of hospital at R.S.Puram, Coimbatore
- ❖ 1994 - Introduced Phaco emulsification surgery (without stitch) for Cataract for the first time in this region.
- ❖ 1994-98 - Introduced Multi Scan Lasik for the first time in India
- ❖ 2002
 - Opening of hospital at Peelamedu, Coimbatore
 - Wave front based Esiris Custom Lasik for the first time in India
 - Introduction of DNB Course
 - Introduction of Fellowship Programs in Cataract, Glaucoma, Cornea, Retina and Refractive surgeries
- ❖ 2003-Diabetic Eye Unit and Life Time Vision Project
- ❖ 2004
 - Opening of Hospital at Salem
 - Introduced Epilasik for glass free vision for the first time in South East Asia.
 - Opening of Lotus Baush & Lomb Institute of Optometry.
- ❖ 2007
 - Opening of Hospital at Tirupur
 - Introduction of wavelight laser technology at Tirupur
- ❖ 2008 - Issue of IPO
- ❖ 2009 - Introduction of Intralase Lasik / Zyoptic laser technology
- ❖ 2010
 - Opening of Hospital at Cochin.
 - Opening of Hospital at Mettupalayam
- ❖ 2011 - Introduction of Zyoptix Supracor for the first time in Tamilnadu.
- ❖ 2013 - Opening of Hospital at Mulanthuruthy
- ❖ 2016 - Launching of Kerala's first ReLEx SMILE at Cochin Hospital
- ❖ 2023 - New branch opened at Saravanampatti
- ❖ 2024 - Launching Touchless Bladeless Lasik 1st Time in Salem
- ❖ 2024 - New branch opened at Karur
- ❖ 2024 - Launching Touch Free Glass Free Smart Lasik 1st Time in Kochi

CHAIRMAN SPEECH

Dear Lotus Family

I Kavetha sundaramoorthy chairman of Lotus Eye Hospital and Institute Limited whole heartedly welcome you all for the 28th Annual General Meeting of the company. It's is an euphoric feeling as to chair one more Annual General Meeting successfully as the chairman of the company.

The Financial year 2024-25 has been a year with lot of pros and cons for the health sector. With the advent of Artificial Intelligence all players in the eye care sector are investing more into technology to provide the best health care services to the larger public. The rising population is another fact that can make health care sector a major contributor to the economy of the country. The darker side of Artificial intelligence has been loss of job to employees which can directly affect the spending capacity of the public. The rising population also creates to challenges to the health care sector as more investment needs to be channelized for infrastructure.

The budget for the FY 2025-26 has focused on providing high quality affordable and comprehensive health care to the larger public. This can be a great helping hand to the poor in accessing quality health care. Our company has always focused on providing world class eye services at affordable rates. Our company carries out free eye camps every Sunday under the Chief Ministers scheme.

Last but not the least I take this opportunity to remember our founder SK sundaramoorthy who worked so hard to create the brand lotus and contribute much more to the society by way of health care services. I again assert the fact that our foundation is and will always be guided by the tenets principles and guidance of our late founder SK Sundaramoorthy

Dr. Kavetha Sundaramoorthy
(Chairman)



MANAGING DIRECTOR'S MESSAGE

Dear Shareholders,

I wish to start my speech by thanking the shareholders for reposing faith on brand Lotus. The journey of 28 years was filled with numerous challenges with the demise of our founder Dr. SK Sundaramoorthy in 2020 being the greatest loss in our journey. I take this opportunity to re-assert the fact that we have always stuck to the values pro-founded by our late founder Dr. SK Sundaramoorthy.

The financial year 2024-25 has been a testing year for our brand Lotus with expansion being our primary focus we have opened another center at Karur on 12th of July 2024, with this the 09th Center of our company commenced its operations. In terms of turnover there was a slight increase in comparison to the last financial year from 48.21 crores to 49.56 crores During the financial year 2024-25 company has invested in capital assets to the tune of 5.57 cores. As always Lotus has never missed in channelizing its resources from investing in cutting edge technology for providing the best eye care services to the larger public. We have put in place the latest machines on all our centers for providing the finest health care services to the larger public and I again affirm the fact that we shall continue to invest in the most advanced and latest technology best suited for providing the best eye care services.

Lotus have the best team of professional doctors supported by PG doctors who are trained at our hospital itself. The co-ordination of our doctors has been outstanding in providing the best eye care services to our patients. In addition our employees have been a pillar of support throughout all these years and their contribution have been pivotal in our journey of growth and we have always strived to retain the best professional talent in our endeavor to provide the best eye care services.

Last but not the least as I always include in all my messages Lotus would not have grown without the confidence and belief of our shareholders. The continuous support of all our shareholders have always motivated us to work hard in wealth creation

Ms. Sangeetha Sundaramoorthy
(Managing Director)





Awards & Recognition

1993 – Best President of Lions Club,Coimbatore.

2002 – Dr Sivareddy Award for Best paper in Kerala Ophthalmic Conference.

2006 – Eye Care Excellence Award by Rotary Club.

2006 – Kannoli Kavalal Award to Dr.S.K.Sundaramoorthy by Lions Clubs International District Region H.

2006 – Best Performer Award by Bausch & Lomb (Highest number of Lasik surgeries performed in the year in India)

2007 – Limca Book of Records Award for conducting International Ophthalmic Conference on Arabian Sea.

2008 – Indian Achievers Award for Health Excellency offered to Dr. S.K.Sundaramoorthy.

2010 – IPL Award to Dr.S.K.Sundaramoorthy by Tamilnadu Ophthalmic Associations.

2012 – Life Time Achievement Award to Dr.S.K.Sundaramoorthy by the Tamilnadu Dr.M.G.R.Medical University.

2013 – Kannoli Vallal Award to Dr.S.K.Sundaramoorthy by Shri. Shanthalinga Ramasamy Adikalar Perur Aadhinam.

2013 – Dr Suryakandhi Oration Award to Dr.S.K.Sundaramoorthy by IMA2012.

2013 – BEACONS for Exemplary Commitment and Impactful Positive Contribution to Tamilnadu – The Times Group, Chennai.



Awards & Recognition

2013 - Life Time Achiever's Award from Guide Trust, Gobi.

2014 - Honour Award to Dr. S.K.Sundaramoorthy by Rotary International.

2014 - Consumer protection award to Dr. S.K.Sundaramoorthy by R T I Council, Kerala.

2014 - International Ophthalmologist Education Award for MII Ret Cam: Smartphone based retinal camera by American Academy of Ophthalmology

2015 - Life time Achievement Award by Indian Medical Association, Coimbatore.

2016 - Occasion Excellence Award to Dr. S.K.Sundaramoorthy by Rotary Club of Metropolis, Tirupur.

2018 - Jammabhumi Legend healthcare award from MPV. Muraleedharan

& Union Minister Mr. Rajyavardan singh rathod at Kochi

2019 - Health Care Leadership Award from World Peace Congress

2019 - Life Time Achievement award from TNOA Conference 2019

2020 - Lotus Eye Hospital Salem ranked 1st runner up in salem business awards 2020

2021 - Budding Entrepreneur – Healthcare award for our **Managing Director**

Ms. Sangeetha Sundaramoorthy in Times Power Awards 2021.

2021 - Excellence in Eye Hospital Award by Times of India

**BOARD OF DIRECTORS
AND COMMITTEES**

LOTUS EYE HOSPITAL AND INSTITUTE LIMITED

CIN : L85110TZ1997PLC007783

Regd. Office & Corporate Office: SF No. 770/12, Avinashi Road, Civil Aerodrome Post,
Coimbatore - 641 014

E-mail: companysecretary@lotuseye.org | Website: www.lotuseye.org

Phone: 0422 4229900 | Fax: 0422 4229933

KEY PEOPLE

Chairman	- Dr. Kavetha Sundaramoorthy
Managing Director	- Ms. Sangeetha Sundaramoorthy
Whole - Time Director & CEO	- Dr. K.S. Ramalingam

Independent Directors

- Dr. S. Natesan
- Mr. Karthik Veeramani
- CA Perumalsamy Mahendran

Chief Financial officer	- Mr. Ramanujam Reghunathan
-------------------------	-----------------------------

Company Secretary & Compliance Officer	- M Achuth Menon
--	------------------

AUDITORS

Statutory Auditors	- M/s. Anbarasu and Jalapathi Chartered Accountants 30C. Alagesan Road, Saibaba Colony, Coimbatore - 641 011
--------------------	---

Internal Auditors	- CA P. Vishnu Adithan, Chartered Accountant, Coimbatore – 641 012
-------------------	--

Secretarial Auditor	- P. Eswaramoorthy & Company Company Secretaries Ramanathapuram, Coimbatore-641 045
---------------------	--

REGISTRAR

Registrar and Share Transfer Agent

M/s.MUFG Intime India Private limited Surya, 35
Mayflower avenue Behind Senthil Nagar
Sowaripalayam Road Coimbatore- 641028 TN Tel.
No. 0422 – 2539835&4958995

Bankers

HDFC Bank Ltd
The Federal Bank Ltd
ICICI Bank Ltd
Canara Bank

COMMITTEES

Audit Committee

CA Perumalsamy Mahendran - Chairman
Dr. Kavetha Sundaramoorthy
Dr. S. Natesan
Mr. Karthik Veeramani

Nomination & Remuneration Committee

Dr. S. Natesan - Chairman
Dr. Kavetha Sundaramoorthy
Mr. Karthik Veeramani
CA Perumal Samy Mahendran

Stakeholders Relationship Committee

Mr. Karthik Veeramani - Chairman
Dr. Kavetha Sundaramoorthy
Dr. S. Natesan
CA Perumal Samy Mahendran

Registered Office - S.F. No. 770/12, Avinashi Road
Civil Aerodrome Post, Coimbatore-641 014

NOTICE TO THE MEMBERS

NOTICE IS HEREBY GIVEN THAT THE 28th ANNUAL GENERAL MEETING OF THE SHAREHOLDERS OF LOTUS EYE HOSPITAL AND INSTITUTE LIMITED WILL BE HELD ON TUESDAY 23rd SEPTEMBER 2025 AT 4 PM THROUGH VIDEO CONFERENCING (“VC”)/OTHER AUDIO VISUAL MEANS (“OVAM”) FACILITY TO TRANSACT THE FOLLOWING:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March, 2025, including the Balance Sheet as at 31st March, 2025, the Statement of Profit and Loss Account and the Cash Flow Statement for the financial year ended on that date and the Reports of the Board of Directors and the Auditors thereon;
2. To appoint a director in the place of Dr. Kavetha Sundaramoorthy (DIN: 02050806) who retires by rotation and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS:

1. To approve the appointment of Secretarial Auditors for a term of 5 years

To consider and if thought fit pass the following resolution as ordinary resolution if it deems fit:

RESOLVED THAT pursuant to Regulation 24A(1A) and 24(1B) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015) 2015 read with Annexure 2 to SEBI Circular dated 31st December 2024 approval is be and hereby accorded for appointment of P Eswaramoorthy practising company secretary holding Membership Number: 6510 as secretarial auditor for a period of 5 years from financial Year 2025-26 to 2029-2030 to conduct the Secretarial Audit of the Company on a remuneration decided by the Board of Directors from time to time.”;

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to fix the annual remuneration plus applicable taxes and out-of-pocket expenses payable to them during their tenure as the Secretarial Auditors of the Company;

RESOLVED FURTHER THAT M Achuth Menon Company secretary be and is hereby authorized to do all such acts, deeds, matters, and things as may be considered necessary, proper, and expedient to give effect to this Resolution.

2. To approve remuneration of Rs 1,00,000 to KS Ramalingam being Non-Independent Non-Executive Director of the company

To consider and if thought fit pass the following resolution as ordinary resolution if it deems fit:

RESOLVED THAT pursuant to Section 197 198 of Companies Act 2013 as amended from time to time read with Regulation 17(6)(ca) of SEBI (Listing Obligations and Disclosure Requirements) 2015 and based on the recommendation of Nomination and Remuneration Committee approval is be and

hereby accorded for payment of remuneration of Rs 1,00,000 per month to KS Ramalingam (DIN:01016571) being the Non-Executive Non-Independent Director of the company.

RESOLVED FURTHER THAT M Achuth Menon Company secretary be and is hereby authorized to do all such acts, deeds, matters, and things as may be considered necessary, proper, and expedient to give effect to this Resolution.

By Order of the Board

For LOTUS EYE HOSPITAL AND INSTITUTE LIMITED

Place: Coimbatore

Date: 12.08.2025

(Sd.)

M Achuth Menon

Company Secretary

NOTES:

1. As you are aware, in view of the situation arising due to COVID-19 global pandemic, the general meetings of the companies shall be conducted as per the guidelines issued by the Ministry of Corporate Affairs (MCA) vide Circular No. 14/2020 dated April 8, 2020, Circular No.17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 05, 2020. The forthcoming AGM/EGM will thus be held through video conferencing (VC) or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM/EGM through VC/OAVM.
2. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM/EGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the EGM/AGM will be provided by CDSL.
3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.

- 
4. The attendance of the Members attending the AGM/EGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
 5. Pursuant to MCA Circular No. 14/2020 dated April 08, 2020, , the facility to appoint proxy to attend and cast vote for the members is not available for this AGM/EGM. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM/EGM through VC/OAVM and cast their votes through e-voting.
 6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM/EGM has been uploaded on the website of the Company at <https://www.lotuseye.org/Investors.php> The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively. The AGM/EGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM/EGM) i.e. www.evotingindia.com.
 7. The AGM/EGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 8, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
 8. In continuation to this Ministry's General Circular No. 20/2020 dated 05.05.2020, General Circular No. 02/2022 dated 05.05.2022 and General Circular No. 10/2022 dated 28.12.2022 and after due examination, it has been decided to allow companies whose AGMs are due in the Year 2023 or 2024, to conduct their AGMs through VC or OAVM on or before 30th September, 2024 in accordance with the requirements laid down in Para 3 and Para 4 of the General Circular No. 20/2020 dated 05.05.2020.
 9. The statement of material facts pursuant to Section 102(1) of the Companies Act, 2013 in respect of Item No.1 and 2 under special business is annexed to the notice.
 10. Details under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards issued by ICSI in respect of the Director seeking re-appointment at the Annual General Meeting is furnished and forms a part of the notice.
 11. Attention of the members is drawn to the provisions of Section 124(6) of the Act which require a Company to transfer in the name of IEPF Authority all shares in respect of which dividend has not been paid or claimed for 7(seven) consecutive years or more. In accordance with the aforesaid provision of the Act read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, the Company has already transferred shares in respect of which dividend declared for the financial year 2016-17.
 12. Those Shareholders who have so far not claimed or collected their dividend for the Financial Year 2016-17 may claim their dividend as per Rule 7 of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 :Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 :Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (i) The voting period begins on **19.09.2025 (9.00am) and ends on 22.09.2025 (5.00pm)**. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date 16.09.2025 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (i) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (i) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (iv) In terms of SEBI circular **no. SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository

Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for **Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual
Shareholders
holding
securities in
demat mode
with NSDL
Depository

- 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <https://eservices.nsdl.com> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
- 2) If the user is not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select “Register Online for IDeAS “Portal or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting
- 4) For OTP based login you can click on <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on **company name or e-Voting service provider name** and you will be re-directed to **e-Voting service provider website** for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
---	--

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(v) Login method for e-Voting and joining virtual meetings for Physical shareholders and shareholders other than individual holding in Demat form.

1. The shareholders should log on to the e-voting website www.evotingindia.com.
2. Click on "Shareholders" module.

3) Now enter your User ID

- a. For CDSL: 16 digits beneficiary ID,
- b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
- c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

4) Next enter the Image Verification as displayed and Click on Login.

5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

(vi) After entering these details appropriately, click on “SUBMIT” tab.

(vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- 
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant Lotus Eye Hospital and Institute limited on which you choose to vote.
- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvii) Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- 

- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; companysecretary@lotuseye.org (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM/EGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM/ EGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM/EGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

- 
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
 7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **15 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **15 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
 8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
 9. Only those shareholders, who are present in the AGM/EGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the EGM/AGM.
 10. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

By Order of the Board

For LOTUS EYE HOSPITAL AND INSTITUTE LIMITED

Place: Coimbatore

Date: 29.05.2025

(Sd.)

Achuthmenon

Company Secretary

In respect of the above material facts, the board of directors of your Company seeking approval of Shareholders by way of passing ordinary resolution as set out in Item No.02 of this.

Additional information on directors recommended for appointment / re- appointment as required under Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with reference to appoint a director in place of Dr. Kavetha Sundramoorthy (Holding Din:02050806), who retires by rotation and being eligible, offers herself for reappointment.

I	Name of Directors	Dr. Kavetha Sundaramoorthy
II	DIN	02050806
III	Date of Birth	30.01.1976
IV	Qualification & Brief resume & nature of his/her expertise inspecific functional areas	Dr. Kavetha Sundaramoorthy serves as Non-Executive Director on the Board of Lotus Eye Hospital and Institute Limited. Dr. Kavetha Sundaramoorthy is an acclaimed and venerable psychiatrist, board certified in both Adult & Child/Adolescent psychiatry, a Harvard University graduate with prestigious Farley Award and has been in practice for past 15 years and more.
V	Disclosure of relationship between directors inter-se	Ms.Sangeetha Sundaramoorthy
VI	Names of listed entities (Other than Lotus) in which the person also holds the directorship and the membership of Committees of the board :	Nil
	1. Directorship	Nil
	2. Chairperson of	
	Board Committees	Nil
	3. Member of Board Committees	Audit committee, Nomination and remuneration committee and stakeholders relationship committee
VII	Number of Board Meetings attended	All four board meetings were attended
	Shareholding	
VII	(No. of Shares, Percentage)	3905356 (18.7791)*

* The shareholding in the details mentioned above is as on 31st March 2025

EXPLANATORY STATEMENT

Special Business 1: To approve the appointment of Secretarial Auditors for a term of 5 years

The Board of Directors, pursuant to the receipt of consent from P Eswaramoorthy, in its meeting held on 29.05.2025 has unanimously approved the appointment of P Eswaramoorthy proprietor of P Eswaramoorthy and Company, Company Secretaries & Registered Trade Mark Agent holding Membership Number 6510 as the Secretarial Auditor.

P Eswaramoorthy is a practising company secretary based out at Coimbatore and has 19 years of experience in practice. The following is a brief profile of P Eswaramoorthy

Mr. P Eswaramoorthy is a distinguished Fellow Member of the Institute of Company Secretaries of India (ICSI). He is holding bachelor's degrees in both Science and Law. Mr. Eswaramoorthy embarked on his professional journey as a Company Secretary with ELGI Software and Technologies Limited, part of the esteemed SARA ELGI Group, where he contributed for four years. Following this, he served M/s Adwaith Group Companies in the same capacity for a year.

In 2006, Mr. Eswaramoorthy initiated his private practice, focusing on a plethora of legal domains including Corporate Laws, SEBI regulations, FEMA, Intellectual Property Laws, Joint Ventures, Mergers, and Demergers. He covers an array of subjects within Corporate Laws, Economic Legislations, Securities Laws, Intellectual Property Rights, Mergers and Amalgamations, Demergers, Spin-offs, and Legal Due Diligence Audits.

P Eswaramoorthy is also a Registered Trademark Attorney, having filed over 650 trademark applications. His passion for legal advisory has propelled him into a decade-long career in legal services.

The Board of Directors has confirmed the compliance under Regulation 24A(1A) and 24A(1B) of SEBI (Listing Obligation and Disclosure Requirements) 2015 and is eligible to be appointed as secretarial auditor of the company.

The proposed fees payable to secretarial auditors shall be Rs. 100,000/- plus all applicable taxes.

The Board of directors hereby recommend to the shareholders for approval of this item of business.



Special Business 2: To approve remuneration of Rs 1,00,000 to KS Ramalingam being Non-Independent Non-Executive Director of the company

Dr KS Ramalingam in the meeting held on 29.05.2025 has requested the Board of Directors to relieve him from the office of CEO and Whole Time Director and put forth the intention to continue as Non-Executive Director. The Board of Directors consented his request to continue as Non-Executive Director.

Based on the recommendation of Nomination and Remuneration committee the Board has approved a payment of remuneration of Rs 1,00,000 per month to Dr KS Ramalingam.

Dr KS Ramalingam is 76 years old with MD in (General medicine) having 42 years of experience as a Clinical Nephrology (Adult and Paediatric) Peritoneal dialysis, Hemodialysis, CAPD & Kidney transplantation. He is one of the renowned doctors in India and is well respected among the Doctors community. He has a proven track record of hospital administration as he is the promoter of Coimbatore Kidney Centre and Specialty Hospitals mainly into treatment of all forms of Kidney disease treatments involving both medical and surgical.

Dr KS Ramalingam comes with a treasure of knowledge about health care and is an able administrator his advice is very much essential for the sustainable growth of the company.

The Board of Directors hereby recommend to the shareholders to approve the payment of remuneration of Rs 1,00,000 to KS Ramalingam

DIRECTORS' REPORT

Dear Shareholders,

Your directors have pleasure in presenting the 28th Annual Report of your Company together with the audited accounts for the year ended 31st March 2025.

FINANCIAL RESULTS

(Rs. in Lakhs)

PARTICULARS	31.03.2025	31.03.2024
	(Current year)	(Previous year)
Income from Operations and other income	5,086.38	4951.26
Less: Expenses	4,949.10	4550.48
Add/Less: Exceptional Items	0.98	0.59
Profit /(Loss) before Tax	138.26	401.37
Less: Provision for Taxes:		
Current tax	36.34	100.19
Deferred Tax	27.99	9.73
Profit / (Loss) after tax	73.93	291.45

FINANCIAL HIGHLIGHTS:

During the year under review company has increased its turnover and the company has set the path of expansion by opening a new center at Karur. Ours is a net debt zero company. The net profit of the company has gone down due to the expansion path as company has opened new center at Karur.

DIVIDEND:

The company has not declared any dividend during the financial year under review.

SHARE CAPITAL:

The Paid up equity share capital as on 31st March, 2025 was 2,079.63 Lakhs. During the year under review, the Company has not issued any shares to the Shareholders. The company has neither issued shares with differential voting rights nor granted stock options or sweat equity shares.

UNPAID DIVIDEND:

Pursuant to Section 124 of Companies Act 2013 the transfer of unclaimed dividend shall commence from the financial year 2024-25. The data pertaining to the unpaid dividend as on 31st march 2025 is hereby mentioned below:



Financial Year	Date of declaration of dividend	Final date of claiming dividend	Unclaimed dividend
2017-18	24-08-2018	20-010-2025	99749
2020-21	17-09-2021	17-09-2028	335508.05
2021-22	22-09-2022	22-09-2029	289225
2022-23	25-09-2023	25-09-2030	275950.50

FINANCE:

Cash and cash equivalents as at 31st March, 2025 was Rs 201.11. Lakhs. The Company continues to focus on prudent management of its working capital, receivables, inventories and other working capital parameters which are kept under strict check and compliance through continuous monitoring.

TRANSFER TO RESERVE:

During the financial year under review no amount was transferred to reserves

DEPOSITS:

During the year under review, your company has neither accepted nor repaid any deposits from public covered under Sections 73 to 76 or any other relevant provisions of the Act and rules framed there under.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

During the financial year under review, your Company has not given any loans or guarantees covered under the provisions of section 186 of the Companies Act, 2013.

The details of the investments made by the company is given in the notes to the financial statements.

CORPORATE SOCIAL RESPONSIBILITIES:

During the financial year under review the provisions of Section 135 of Companies Act 2013 did not apply. During the last financial year 2023-24 when the CSR provisions became applicable for the first time the company has utilized an amount of Rs 50,000 as part of on-going project involving promotion of healthcare and the remaining amount of 7,27,900 was transferred to unspent bank account maintained with Canara bank.



DIRECTORS:

Directors retiring by rotation:

Ms. Kavetha Sundaramoorthy (DIN:2050806, Director of the Company retires by rotation at the forthcoming Annual General Meeting and being eligible, offers herself for re-appointment.

Information regarding the Directors seeking appointment/re-appointment:

Material information regarding the Directors seeking appointment /re-appointment as required by Regulation 36 of the SEBI (LODR) Regulations, 2015 has been given in the Notice convening the ensuing Annual General Meeting and in the Statement pursuant to Section 102 of the Act.

Declaration by Independent Directors:

All Independent Directors have given declaration that they meet the criteria of independence as laid down under section 149(6) of the Companies Act, 2013 and regulation 16(1)(b) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

In opinion of the Board with Independent Directors possess integrity, expertise and experience (including the proficiency).

Familiarisation Programme:

Your Company has adopted a policy on Familiarization programme of Independent Directors. During the year under review one programme was conducted by the company. Details of such programme for familiarisation of the Independent Directors are put on the website of the Company at the following web-link: <https://www.lotuseye.org/Investors.php>.

Statutory Disclosure:

None of the Directors of the Company is disqualified as per the applicable provisions of the Act. A certificate in this regard is certified by the Secretarial Auditors is attached with the Corporate Governance Report.

BOARD EVALUATION:

The Board has carried out an evaluation of its own performance, the Directors performance individually as well as evaluation of the working of its Audit Committee and Nomination and Remuneration Committee internally. As part of evaluation company has distributed questionnaires to various directors and has received their evaluation as required under law.



REMUNERATION POLICY:

The Policy on Board Diversity and Nomination & Remuneration Policy as recommended by the Nomination & Remuneration Committee has been approved by the Board of Directors. The said policies are annexed to the Board's Report and are also available on the Company's website at the following link: <https://www.lotuseye.org/Investors.php>.

MEETINGS:

During the year, four Board Meetings, four Audit Committee Meetings, one Nomination and Remuneration Committee Meeting was convened and held. One Stakeholder Relationship Committee Meetings for the financial year 2024-25 were held. The details of there are given in the Corporate Governance Report. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

COMMITTEES OF THE BOARD:

Currently the Company has three Committees i.e. Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee. All the committees are Independent under the Chairmanship of an Independent Director. The details of the compositions, terms of reference, meetings, etc., of said Committees are given in the Report on Corporate Governance which forms part of this Report.

DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- I. In the preparation of the annual accounts the applicable accounting standards have been followed.
- II. Appropriate accounting policies have been selected and applied consistently, and judgments and estimates that have been made are reasonable and prudent so as to give a true and fair view of the company at the end of the financial year and of the company for that period.
- III. Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the companies Act, 2013 for safeguarding the assets of the company and for the preventing and detecting fraud and other irregularities.
- IV. Annual accounts have been prepared on going concern basis.

- 
- v. Internal financial controls to be followed by the company were followed and those internal financial controls are adequate and were operating effectively.
 - vi. Devised proper systems to ensure compliance with the provisions of all applicable laws and that such system were adequate and operating effectively.

RELATED PARTY TRANSACTIONS:

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of the business. There were no subsequent material modifications to the existing related party transactions. There are no materially significant related party transactions made by the company with Promoters, Key Managerial Personnel or other designated persons which may have potential conflict with interest of the company at large. Accordingly, no transactions are being reported in Form AOC-2 in terms of Section 134 of the Act, read with Rule 8 of the Companies (Accounts) Rules, 2014.

SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS:

There are no significant and material orders passed by the Regulators/Courts/Tribunals which would impact the going concern status and Company's operations in future.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There are no material changes and commitments affecting financial position of the Company which have occurred between the end of the financial year of the Company to which the Financial Statements relate and date of this report.

CODE OF CONDUCT:

The Board of Directors has approved a Code of Conduct which is applicable to the Members of the Board and all employees in the course of day to day business operations of the company. The Company believes in "Zero Tolerance" against bribery, corruption and unethical dealings / behaviors of any form and the Board has laid down the directives to counter such acts. The code laid down by the Board is known as "Code of Conduct" which forms an Appendix to the Code. The Code has also been posted on the Company's website at the following link: <https://www.lotuseye.org/Investors.php>.



The Code lays down the standard procedure of business conduct which is expected to be followed by the Directors and the designated employees in their business dealings and in particular on matters relating to integrity in the work place, in business practices and in dealing with stakeholders. The Code gives guidance through examples on the expected behavior from an employee in a given situation and the reporting structure.

All the Board Members and the Senior Management personnel have confirmed compliance with the Code. All Management Staff were given appropriate training in this regard.

KEY MANAGERIAL PERSONNEL:

The details of the Key Managerial Personnel of the Company, their appointment / cessation during the year under review and remuneration are given in the draft Annual Return. Further the board took note that the compliance officer is one level below the board as per the SEBI circular dated 12th Dec, 2024

VIGIL MECHANISM / WHISTLE BLOWER POLICY:

Your Company believes in the conduct of the affairs of its constituents in a fair and transparent manner by adopting highest standards of professionalism, honesty, integrity and ethical behavior.

Your Company is committed to developing a culture where it is safe for any Whistle Blower to raise concerns about any poor or unacceptable practice and any event of misconduct. The alleged misconduct may be classified in many ways; namely, violation of a law, rule, regulation and / or a direct threat to public interest, such as health and safety violations and corruption.

Your Company will not tolerate any form of victimization and will take appropriate steps to protect a bona fide whistle blower and shall treat any retaliation as a serious disciplinary offence that merits disciplinary action. The Company will protect the identity of the whistle blower, if so desired, provided that the whistle blower will need to attend any disciplinary hearing or proceedings as may be required for investigation of the complaint. The mechanism provides for a detailed complaint and investigation process. If circumstances so require, the employee can make complaint directly to the Chairman of the Audit Committee. The said mechanism can also be availed by the Directors of the Company.

SUBSIDIARY COMPANIES:

The Company does not have any subsidiary company.

CHANGE IN NATURE OF BUSINESS, IF ANY:

During the year under review, there is no change in nature of business of the Company.



'Whistle Blower Policy' of your Company is available on the website of the Company at the following link: <https://www.lotuseye.org/Investors.php>.

PREVENTION OF INSIDER TRADING:

The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company. The Code requires pre-clearance for dealing in the Company's shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. Company has put in place pan level freezing for all designated persons so as to prohibit dealing in shares of the company. The Board is responsible for implementation of the Code. The compliance of the regulation and code is reviewed by the Audit committee on a regular basis.

The same Code is available in the website of your Company at the following link:
<https://www.lotuseye.org/Investors.php>.

All Board of Directors and the designated employees have confirmed compliance with the Code.

AUDITOR'S REPORT:

The observation made in the Auditors' Report read together with relevant notes thereon are self-explanatory and hence, do not call for any further comments under Section 134 of the Companies Act, 2013.

AUDITORS:

M/s. Anbarasu & Jalapathi, Chartered Accountants are your statutory auditors, who shall hold office till the conclusion of 30th Annual General Meeting i.e., FY 2026-27.

INTERNAL AUDITORS:

CA P Vishnu Adithan, Practicing Chartered Accountant was appointed as the Internal Auditors of the Company for the financial year 2024-25 pursuant to Section 138(1) of the Act.

SECRETARIAL AUDIT/AUDITORS:

Pursuant to provisions of section 204 of the Companies Act, 2013 read with Regulation 24A (1C) the Board of directors have appointed Mr.P .Eswaramoorthy (CP No. 7069) Company Secretary in Practice for a period of 5 years subject to approval of shareholders in the ensuing Annual General Meeting from Financial year 2025-26 to 2029-30 to undertake the Secretarial Audit of the Company.

DIRECTORS & KMP:

Neither there was appointment nor there was resignation of directors or KMP during the financial year 2024-25.

SECRETARIAL AUDIT REPORT:

As required under section 204 (1) of the Companies Act, 2013 the Company has obtained a secretarial audit report. The Company Secretary in Practice has made his observation in Secretarial Audit Report. (MR-3) which is annexed herewith as “**Annexure – IV**.”

COST AUDIT:

The applicability of cost audit under section 148 is not applicable

DRAFT ANNUAL RETURN:

The details forming part of the draft Annual Return in form MGT-7 is posted in the website <https://www.lotuseye.org/Investors.php>.

BUSINESS RISK MANAGEMENT:

The Company has a robust Risk Management plan to identify, evaluate business risks and opportunities. This framework seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company’s competitive advantage. As part of the Risk Management framework, the Company reviewed periodically the various risks and finalized the mitigation plans. The identified risk areas were covered by the Internal Audit and major risks were discussed periodically. Since company is governed by NBEMS the company has a risk management plan for each and every department.

PARTICULARS OF EMPLOYEES:

Statements containing the details as required in terms of the provisions of Section 197 of the Act read with Rule 5(1), (2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are attached to this Report as **Annexure –I**.

CORPORATE GOVERNANCE AND MANAGEMENT DISCUSSION & ANALYSIS REPORT:

The Corporate Governance and Management Discussion & Analysis Report, which form an integral part of this Report, is set out as separate Annexure, together with the Certificate from the Auditors of the Company regarding compliance with the requirements of Corporate Governance as stipulated in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (Refer “**Annexure – II**” and “**Annexure – III**”

CONSERVATION OF ENERGY, TECHNOLOGY, ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The details of Energy, Technology, Absorption, Foreign Exchange Earnings and Outgo are as under:

a) Conservation of Energy:

Steps taken for conservation	The operation of the Company being service related requires normal consumption of electricity. The Company is taking every necessary step to reduce the consumption of energy.
Steps taken for utilizing alternate sources of energy	Nil
Capital investment on energy conservation equipments	In view of the nature of activities carried on by the Company, there is no capital investment on energy conservation equipments.

b) Technology Absorption:

Efforts made for technology absorption	Nil
Benefits derived	Nil
Expenditure on Research & Development, if any	Nil
Details of technology imported, if any	Nil
Year of import	Nil
Whether imported technology fully absorbed	Nil
Areas where absorption of imported technology has not taken place, if any	Nil

c) Foreign Exchange Earnings/ Outgo (Rs. In Lakhs):

Earnings	Nil
Outgo	Nil



DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-harassment policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. There are no complaints received by the company during the financial year 2024-25.. Company has carried out an awareness program for all its woman employees regarding their various rights under the Act while working in an organization.

The Company has complied with the provisions of the Maternity Benefits Act, 1961.

INSOLVENCY AND BANKRUPTCY CODE 2016:

There was no application made under the Insolvency and Bankruptcy Code 2016 during the financial year under purview.

FRAUDS UNDER SECTION 143(12) REPORTED BY STATUTORY AUDITORS:

There were no instances of fraud reported during the financial year 2024-25 by the statutory auditors.

COMPLIANCE WITH SECRETARIAL STANDARDS:

Company is in compliance with secretarial standards issued by the Institute of Company Secretaries of India.

LISTING WITH STOCK EXCHANGES:

The company has listed its equity shares in Bombay Stock Exchanges and National Stock Exchanges.

QUALIFICATION ADVERSE REMARKS RESERVATIONS BY AUDITORS IF ANY:

There are no Qualification, Adverse Remarks Reservations by statutory Auditors in the Independent Auditors Report and secretarial auditors in the Independent Auditors Report.

DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS AND INTERNAL AUDIT:

Your Company has put in place, well defined and adequate Internal Control System and Internal Financial Control (IFC) mechanism commensurate with size, scale and complexity of its operations to ensure control of entire business and assets. The functioning of controls is regularly monitored to ensure their efficiency in mitigating risks. A comprehensive internal audit department functions in house to continuously audit and report gaps if any, in the diverse business verticals and statutory compliances applicable.



BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

A Business Responsibility And Sustainability Report describing the initiatives taken by the Company from an environmental, social and governance perspective, as required in terms of the provisions of Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Since the compliance is on voluntary basis and the company does not fall under the threshold for mandatory compliance company is not obliged to annex the same with the annual report.

ACKNOWLEDGEMENTS:

Your Company and its Directors wish to extend their sincerest thanks to the Members of the Company, Bankers, State Government, Local Bodies, Customers, Suppliers, Executives, Staff at all levels for their continuous cooperation and assistance.

Place: Coimbatore

Date: 29.05.2025

For and on behalf of the Board
(Sd/-)

Ms. Sangeetha Sundaramorthy
Managing Director

Annexure -I

STATEMENT OF DISCLOSURE OF REMUNERATION UNDER SECTION 197 OF COMPANIES ACT, 2013 AND RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

I. Ratio of the remuneration of each director¹ to the median remuneration of the employees of the Company for the financial year 2024-25:

Sl. No.	Name	Designation	Ratio
1.	Sangeetha Sundaramoorthy	Managing Director	21.93:1
2.	KS Ramalingam	Whole-Time Director	6.27:1

(ii) Percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary and Manager in the financial year 2024-25:

Sl. No.	Name	Designation	% increase in remuneration
1.	Ms. Sangeetha Sundaramoorthy	Managing Director	Nil
2.	KS Ramalingam	Chief Executive Officer	Nil
3.	ReghunathanRamanujam	Chief Financial Officer	8.57
4.	Achuth Menon	Company Secretary	10.75

(iii) The percentage increase in the median remuneration of employees in the financial year 2024-25 : 5.97

(iv) The number of permanent employees on the rolls of Company:

There were 348 number of permanent employees on the rolls of the Company as on 31.03.2025.

(v) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

Average percentile increase in The salary of employees is 10.75% in comparison to 3.48% increase in the managerial remuneration to Chief Financial officer & Company secretary during the year in the normal course of business, keeping in view the Company's performance, increased responsibilities, and industry benchmarks.

(vi) Affirmation that the remuneration is as per the remuneration policy of the Company:

It is hereby confirmed that the remuneration paid during the year 2024-25 is as per the Nomination & Remuneration Policy of the Company.

STATEMENT OF DISCLOSURE OF REMUNERATION UNDER SECTION 197 OF COMPANIES ACT, 2013 AND RULE 5(2) AND 5(3) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

As no employee is drawing salary more than Eight Lakhs Fifty Thousand per month / One Crore and Two Lakhs per annum and the above provisions shall not apply to the company.

REPORT ON CORPORATE GOVERNANCE

(Annexure to the Twenty Eighth Directors' Report 2024-25)

Introduction

Corporate Governance report is a document outlining the strong pillars of governance adhered by the company. . This report supplements the stakeholders to understand the efforts invested by the company in achieving good corporate governance standards. India being a dynamic country where changes are taking place every hour this report enlightens the stakeholders in understanding the fact of how much the management and company has strived to ensure good corporate governance. The growing impetus to bring more definition and perspicuity into the operative dynamics of the company is just a constant endeavor to bring more absolute enlightenment to the stakeholders of the company. Keeping in mind the interest of stakeholders the regulators are treading a path where strict compliances and policies need to be followed by the companies in order to enhance the shareholders wealth as well as attain good corporate governance standards. This attitude of the regulators to make companies accountable and adhere to law helps in streamlining the existing processes, enhance shareholders wealth and thereby achieve a good standing within the country.

Date of Report

The information provided in this Report on Corporate Governance for the purpose of unanimity is as on 31st March, 2025. This Report is updated as on the date of the Report wherever applicable.

1. The Company's philosophy on Corporate Governance

The Fundamental objective of our corporate governance policies are based on the highest levels of transparency, accountability in terms of stewardship responsibility towards shareholders, creditors, employees and society at large. Your company is committed to ensure high standards of corporate governance on a sustained basis.

2. Board of Directors

Composition

As on 31st March 2025, the strength of the Board is Six Directors.. There are three Independent Directors Two executive Directors and One Non-Executive Director out of which two are women directors. Applicability of appointment of woman Independent Directors does not apply to company. The composition of Board is in compliance with the requirements of Regulation 17(1) of the SEBI (LODR) Regulations, 2015.

Name of the Director	Category	No. of Directorship *	Membership and / or Chairperson of Committees#	
			Member	Chairman
Dr.Kavetha Sundaramoorthy	Non-Executive - Promoter	1	2	Nil
Ms.Sangeetha Sundaramoorthy	Executive - Promoter	1	Nil	Nil
Dr. KS Ramalingam	Executive Director& CEO	2	Nil	Nil
Dr S Natesan*	Non-Executive Independent –	1	2	Nil
Mr Karthik Veeramani**	Non-Executive Independent –	1	2	1
MrPerumalsamy Mahendran***	Non-Executive Independent –	1	2	1

*Excluding private limited companies, foreign companies, companies under Section 8 of the Companies Act, 2013 and alternate directorships but including Lotus Eye Hospital and Institute Limited.

Includes only positions held in Audit Committee and Stakeholders' Relationship Committee in Indian public limited companies including Lotus Eye Hospital and Institute Limited.

Except Dr. Kavetha Sundaramoorthy and Ms. Sangeetha Sundaramoorthy, no other director of the Company is related to any other director on the Board of the Company.

Except Dr. Kavetha Sundaramoorthy (Non-Executive – Promoter) who is holding 3905356 Thirty Nine Lakh five thousand fifty six only)and Mr Karthik Veeramani (Non- Executive – Independent who is holding 127 shares, no other non-executive director holds shares in the company

* S Natesan became member of Stakeholders Relationship committee with effect from 12th August 2024

** Mr Karthik Veeramani became chairman of Stakeholders Relationship committee with effect from and member of Audit committee with effect from 12th August 2024

*** Mr Perumalsamy Mahendran became chairman of Audit committee and member of Stakeholders Relationship committee with effect from 12th August 2024

During the FY 2024-25 three Independent Director DR Kaarthikeyan, CA M Alagiriswamy and Dr Yogesh shah ceased to hold office with effect from 24th September 2024

All the directors attended the Last Annual General Meeting held on 13th August 2024.

In the opinion of the board, the independent directors fulfill the conditions specified in these regulations and are independent of the management

3. Key Managerial Personnel of the Company

Sl. No	Name	Designation
1.	Reghunathan Ramanujam	Chief Financial Officer
2.	M Achuth Menon	Company Secretary

There has been no changes to the Key Managerial Personnel during the financial year under review

Meetings

The Board met four times during the year under review i.e. on 27th May 2024, 12th August 2024, 12th November 2024 and 12th February 2024 Attendance details of each director at the Board Meetings, Committee Meetings and at the last Annual General Meeting are set out below.

Name of the Directors	Board Meeting (4)	Audit Committee (4)	Nomination and Remuneration Committee (4)	Stakeholder Relationship Committee (2)	Annual General Meeting
Mr.D.R.Kaarthikeyan	2	2	0	1	Yes
Dr. Yogesh Shah	2	2	0	-	Yes
Ms. Sangeetha Sundaramoorthy	4	-	-	-	Yes
Dr. .Kavetha Sundaramoorthy	3	3	1	1	Yes
Dr. K S Ramalingam	4	-	-	-	Yes
Mr M.Alagiriswamy	2	2	0	1	Yes
Dr S Natesan*	4	4	1	0	Yes
Mr KarthikVeeramani**	4	2	1-	1	Yes
Mr Perumalsamy Mahendran***	4	4	1	1	Yes

- 
- * S Natesan was inducted into stakeholders relationship committee with effect from 12.08.2024
 - ** Karthi Veeramani was inducted into Audit committee and Nomination and Remuneration committee with effect from 12.08.2024
 - *** Perumalsamy Mahendran was inducted into Nomination and Remuneration committee and Stakeholders Relationship committee with effect from 12.08.2024

The figures within brackets denote the number of meetings held during the period 1st April 2024 to 31st March 2025.

The names of the listed entities where the person is a director and the category of directorship other than Lotus Eye Hospital and Institute Limited

Change in the Board of directors during FY 2024-25

During the Financial year under review DR Kaarthikeyan, M Alagirisamy and Yogesh shah three independent directors demitted office due to completion of tenure of 10 years with effect from 24th September 2024..

Familiarisation Programme

Your Company has adopted policy on Familiarization programme of Independent Directors. During the year under review one programme was conducted by the company details of such programme for familiarisation of the Independent Directors are put on the website of the Company at the following web-link: <https://www.lotuseye.org/Investors.php>.

Skills/expertise/competence of the board of directors

The Board of Directors is satisfied that the current composition has an appropriate mix of knowledge, skills, experience, diversity and independence. The Board provides leadership, strategic guidance, objective and an independent view to the Company's management while discharging its fiduciary responsibilities, thereby ensuring the management adheres to high standards of ethics, transparency and disclosure



Name of the Director	Directorship	Skills/expertise/competence
Dr.SNatesan	Independent Director	He is a leading doctor in Erode. He has over four decades of experience in various facets of healthcare industry
Sangeetha Sundaramoorthy	Managing Director	She has vast experience in management. Her experience cuts across Financial Compliance Business and administration related aspects.
Dr.KavethaSundaramoorthy	Chairman	Dr. Kavetha Sundaramoorthy is an acclaimed and venerable psychiatrist, board certified in both Adult & Child/Adolescent psychiatry, a Harvard University graduate with prestigious Farley Award and has been in practice for past 15 years and more
Dr.KS Ramalingam	Whole-Time Director & CEO	He is one of the renowned doctor in Coimbatore. He is the promoter of Coimbatore Kidney Centre and has over four decades of experience in various facets healthcare industry
Karthik Veeramani	Independent Director	He is a leading Real estate consultant in the city of Coimbatore. He can help the organization in providing inputs to its expansion plans.
Perumalsamy Mahendran	Independent Director	He is one of the leading practicing Chartered accountant in Coimbatore. His experience cuts across Statutory Audit, Taxation Internal Audit and Taxation Audit.

LOTUS requires skill / expertise / competencies in the areas of leadership, finance, capital projects, governance, Government liaison, Hospital Management and new medical advancements and technology absorption, to efficiently carry on its Healthcare and Educational activities



Board of Directors	S Natesan	Sangeetha Sundaram oorthy	Kavetha Sundaramoor thy	KS Ramalingam	Karthik Veeraman i	Perumalsamy Mahendran
Business leadership	✓	✓	✓	✓	✓	✓
Financial Expertise	-	-	-	-	-	✓
Strategic planning and General Management	✓	✓	✓	✓	✓	-
Understanding of Technology Innovation	-	✓	✓	✓	✓	✓
Ability to identify Risk	✓	✓	✓	✓	✓	✓
Legal & Compliances	-	✓	-	-	-	✓
Health sector expertise	✓	✓	✓	✓	-	-

4. Audit Committee

Terms of Reference

Terms of reference of the Audit Committee includes overseeing the financial reporting process, reviewing of financial statements, ensuring compliance with the regulatory guidelines, reviewing of internal audit reports, recommending appointment and remuneration of auditors to the Board of Directors and reviewing adequacy of internal control systems and internal audit function and other matters specified for Audit Committee under Section 177 of the Companies Act, 2013 and the Part C of the Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All recommendations made by the audit committee during the year were accepted by the Board. The details of terms of reference of audit committee can be found on your company's website at the following link: <https://www.lotuseye.org/Investors.php>.

Composition& Meetings:

There were four meetings held during the year i.e. on 27th May 2024, 12th August, 2024, 12th November, 2024, 12th February, 2025

CFO, Representative of Statutory Auditors and Internal Auditors attended the meeting as Invitees. Company Secretary of the Company also acts as the Secretary to the Committee.

Composition of the Audit Committee is as follows:

Sl.No.	Name of the Members	Category	Meetings Attended
1	CA M.Alagiriswamy*	Chairman - Independent – Non-Executive	2
2	D.R Kaarthikeyan**	Member - Independent – Non-Executive	2
3	Dr Kavetha Sundaramoorthy	Member-Non-Independent- Non Executive	3
4	Dr S Natesan	Member - Independent – Non-Executive	4
5	Dr Yogesh shah***	Member - Independent – Non-Executive	2
6	CA Perumalsamy Mahendran #	Chairman - Independent – Non-Executive	4
7	Karthik Veeramani##	Member - Independent – Non-Executive	2

* CA M Alagiriswamy ceased to be the chairman and member with effect from 24.09. 2024

**D.R Kaarthikeyan ceased to be a member with effect from 24.09. 2024

***Dr Yogesh shah ceased to be a member with effect from 24.09. 2024

CA PerumalsamyMahendran became chairman of Audit committee with effect from 12.08.2024

Karthik Veeramanibecame member of Audit committee with effect from 12.08.2024

5. Nomination and Remuneration Committee

Terms of Reference

The terms of reference of the Nomination & Remuneration Committee cover all the areas mentioned under Section 178 of the Companies Act, 2013 and Part D of the Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The broad terms of reference of the Committee includes:

- (i) Formulating the criteria for determining qualifications, positive attributes and independence of a Director;
- (ii) Recommending to the Board a policy relating to the remuneration for the directors, key managerial personnel and other employees of the Company;
- (iii) Identifying persons who are qualified to become directors and who may be appointed in senior management;
- (iv) Evaluating the performance of all Directors.
- (v) Recommendation of remuneration of Senior Management personnel

Composition & Meetings:

There were two meetings held during the year i.e. on 12th February 2025
Company Secretary of the Company also acts as the Secretary to the Committee.

Composition of Nomination and Remuneration Committee is as follows:

Sl. No.	Name of the Members	Category	Meetings Attended
1	Mr. D.R.Karthikeyan*	Chairman - Independent – Non-Executive	0
2	Dr. Yogesh Shah**	Member - Independent – Non-Executive	0
3	M Alagiriswamy***	Member - Independent – Non-Executive	0
4	S Natesan#	Chairman –Independent – Non-Executive	1
5	Kavetha Sundaramoorthy	Member- Non-Independent Non-Executive	1
6	PerumalsamyMahendran##	Member - Independent – Non-Executive	1
7	Karthik Veeramani###	Member - Independent – Non-Executive	1

* D.R.Karthikeyan ceased to be the member and chairman with effect from 24.09.2024

**Dr.Yogesh Shah ceased to be the member with effect from 24.09.2024

*** CA M Alagiriswamy ceased to be the member with effect from 24.09.2024

S Natesan became the chairman of the committee with effect from 12.08.2024

Perumalsamy Mahendran became member of the committee with effect from 12.08.2024

###Karthik Veeramani became member of the committee with effect from 12.08.2024

Performance Evaluation Criteria for Independent Directors

Performance of each of the Independent Directors are evaluated every year by the entire board with respect to various factors like attendance at meetings; contribution at meetings; independence of judgment; direction / guidance to senior management, etc.

6. Remuneration Policy

The Policy on Board Diversity and Nomination & Remuneration Policy as recommended by the Nomination & Remuneration Committee have been approved by the Board of Directors. The said policies are annexed to the Board's Report and are also available on the Company's website at the following link: <https://www.lotuseye.org/Investors.php>.

The Non-Executive Independent Directors of the Company do not have any other material pecuniary relationships or transactions with the Company or its directors, senior management, subsidiary or associate, other than sitting fees.

During financial year 2024-25 Non-Executive Independent Directors were paid sitting fee at the rate of 50,000/- and Rs 25,000/- for attending meeting(s) of the Board and Committees thereof.

Details of the Sitting fees paid and Commission payable to the Non-Executive Directors of the Company for Financial year 2024-2025 are as under:

(Rs. In Lakhs)

Name of the Directors	Sitting Fees Paid
Mr. D.R.Karthikeyan	1.00
Mr. Yogesh Shah	0.50
Mr. Kavetha Sundaramoorthy	0.90
Mr M.Alagiriswamy	1.00
Mr S Natesan	1.40
Mr Karthik Veeramani	1.40
Mr Perumalsamy Mahendran	1.40
Total	7.60

7. Stakeholder's Relationship Committee

The Committee shall consider and resolve the grievances of the security holders of the listed entity including complaints related to transfer of shares, non-receipt of annual report and non-receipt of declared dividends etc.

Committee met once for the year under review i.e. on 27th May 2024.

Sl.No.	Name of the Members	Category	Meeting Attended
1	D.R.Karthikeyan*	Chairman - Independent – Non-Executive	1
2	CA M.Alagiriswamy**	Member - Independent – Non-Executive	1
3	Kavetha Sundaramoorthy	Member – Non Independent Non-Executive	1
4	Karthik Veeramani#	Chairman - Independent – Non-Executive	1
5	PerumalsamyMahendran##	Member - Independent – Non-Executive	0
6	S Natesan ###	Member - Independent – Non-Executive	0

*D.R.Karthikeyan ceased to be the member and chairman with effect from 24.09.2024

** CA M Alagiriswamy ceased to be the member with effect from 24.09.2024

#Karthik Veeramani became chairman of the committee with effect from 12.08.2024

Perumalsamy Mahendran became member of the committee with effect from 12.08.2024

###S Natesan became member of the committee with effect from 12.08.2024

Company Secretary of the Company is the Compliance Officer. Details of the same can be found on the website of the company at the following link: <https://www.lotuseye.org/Investors.php>

8. Investor Complaints during the Financial year 2024-25

During the year the company has not received any complaints from the investors and there were no outstanding complaints as on 31.03.2025.

9. Remuneration to Managing Director and Whole Time Director (In Lakhs)

Sl.No	Name	Amount
1.	Sangeetha Sundaramoorthy	42.00
2.	KS Ramalingam	12.00

10. Annual General Meeting

The date, venue and time of the Annual General Meetings held during the preceding three years are given below:

Financial year	Details of Meeting	Date and time of Meeting	Venue	Special Resolutions
2021-22	25 th AGM	22.09.2022 – 04:00 PM	Through video conferencing („vc”)/other audio visual means („ovam”).	No
2022-23	26 th AGM	25.09.2023 – 04:00 PM	Through video conferencing („vc”)/other audio visual means („ovam”).	No
2023-24	27 th AGM	13.08.2024	Through video conferencing („vc”)/other audio visual means („ovam”).	No

No Special Resolutions was required to be put through postal ballot during the financial year under review.

No Special Resolutions on matters requiring postal ballot are placed for Shareholders’ approval at the ensuing annual General Meeting.

11. Means of Communication

Your Company has promptly reported all material information including declaration of quarterly financial results, etc. to all Stock Exchanges where the securities of the Company are listed. Such information is also simultaneously displayed immediately on the Company’s website <https://www.lotuseye.org/Investors.php> The quarterly, half yearly and annual financial results and other statutory information were generally communicated to the shareholders by way of an advertisement in an English newspaper and in a vernacular language newspaper as per requirements of the SEBI (LODR) 2015..

12. General Shareholders Information:

- a. AGM Date, Time and Venue : 23rd September 2025, 4.00pm, Video Conferencing.
- b. Financial Calendar : 1st April 2024 to 31st March 2025
- c. Date of Book Closure : 17.09.2025 to 23.09.2025

d. Listing of

i. Equity Shares

: BSE Limited (BSE)
PhirozeJeejeebhoy Towers, Dalal Street,
Mumbai – 400 001

: National Stock Exchange of India Limited (NSE),
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

ii. Listing Fees

: Annual Listing fees for the year 2024-25 have
been paid to all the above mentioned Stock
Exchanges and there is no fee outstanding as on
date.

e. Custodial Fees

: Custodial fees paid to the CDSL and NSDL and
there is no fees outstanding as on date.

f. Stock Exchange Security Code

:BSE - Scrip Code : 532998 – Scrip Name :
LOTUSEYE For Equity Shares NSE - Scrip Code :LOTUSEYE

g. Demat ISIN Numbers in NSDL &: INE 947I01017 CDSL for Equity Shares

**h. Address of the Registered Office/
Address for Correspondence**

: 1. 770/12, Avinashi Road,
Civil Aerodrome Post,
Coimbatore – 641 014.

2. MUFG Intime India Private Limited
Surya, 35 Mayflower avenue
Behind Senthil Nagar Sowaripalayam Road
Coimbatore- 641028 TN

i. Hospital Branches

: 1.770 Sitra Road, 12, Avinashi Rd, near Passport
Office, Peelamedu, Civil Aerodrome Post,
Coimbatore, Tamil Nadu 641014

2.155B, East Perisamy Road, Opposite to
Chinthamani, North Coimbatore, R.S.Puram,
Coimbatore – 641 002.

- 
3. No.5 (2), Gajalakshmi Theatre Road, Near Valarmathi
Bus Stop, Tirupur – 641 601,
 4. 86, Brindhavan Road, Fairlands, Salem – 636 016.
 5. No.140, Coimbatore Main Road, Opp.Bus Stand,
Mettupalayam – 641 031
 6. No.53/33A – 33F, Thejas Towers, SA Road,
Kadavanthara, Cochin – 682 020.
 7. 229A, Kurisingal House, Mulanthuruthy Post,
Cochin – 682 314.
 8. SF.No:86/1, Site No:2 TRM Avaneue, Sathy Rd,
Saravanampatti Coimbatore Tamil Nadu 641035
 9. Door No.28,28/2 Sengunthapuram Main Road Karur -639002

j. Registrar & Share Transfer / Demat Agents:

M/s.MUFG Intime India Private limited Surya, 35 Mayflower avenue Behind Senthil Nagar
Sowaripalayam Road Coimbatore- 641028 TN Tel. No. 0422 – 2539835&4958995

Email: jayakumar.kandaswamy@in.mpms.mufig.com

k. Share Transfer System:

99.99% of the Company's paid-up equity capital is held in dematerialized form (only 600 shares are held in the physical form). However, the transfer requests are processed within 15 days from the date of such request, subject to the documents being valid and complete in all respects. Based on a SEBI directive, the equity shares of the Company are permitted to be traded only in dematerialized form

I. Category of Shareholder & Distribution of Shareholding

Categories of Shareholders as on 31.03.2025

S. No	Category	No. of Share holders	No. of Shares held	% of paid up Share Capital
1	Promoters and Promoters group	4	83,64,302	40.22
2	Bodies Corporate	45	30,47,997	14.66
3	Individuals	11289	88,90,387	42.74
4	Others	170	4,93,644	2.38
	Total	11508	20796330	100

m. Dematerialization of Shares and liquidity:

The Company has already entered into agreements with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) to enable members of the Company to select the Depository of their choice for holding and dealing in shares in electronic form.

The Shareholders are requested to make use of such facility for maximizing their convenience in dealing with Company's shares. The ISIN (International Securities Identification Number) of the Company is INE 947101017.

As on 31st March 2025, 99.99% of the Company's paid-up equity capital was held in dematerialized form (only 600 shares were held in the physical form).

n. Outstanding ADRs/GDRs or warrants or any convertible instruments, conversion date and likely impact on equity: Not Applicable

o. Commodity price risk or foreign exchange risk and hedging activities: Not Applicable

p. Correspondance: Same as registered office Address

q. Company has not any fund by way of issuance of debt instruments of such entity or any fixed deposit programme or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad : Not Applicable

13. Other Disclosures:

a. Related Party Transactions

Details of related party transactions are disclosed in **32** in Notes on Accounts forming part of the Accounts, as required under Accounting Standard 18 of The Institute of Chartered Accountants of India and all related party transactions are negotiated, on an arm's length basis. There were no materially significant related party transactions with directors, promoters, management, relatives or related companies etc. which had potential conflict, with the interests of the Company at large.

Transactions, in which directors may have substantial interest, are submitted to the Board and the interested directors, neither participates in the discussion, nor do they vote in such matters. Details of related party transactions are reviewed by the Audit Committee periodically.

There were no material related party transactions during the financial year 2024-25

The policy for related party transaction can be viewed at the following link:

<https://www.lotuseye.org/Investors.php>.

b. Compliance by the Company

The company has complied with all applicable provisions and regulations. There are no non-compliances or observations mentioned in the Secretarial Audit report.)

c. Details of establishment of vigil mechanism, whistle blower policy, and affirmation that no personnel has been denied access to the audit committee

The Whistle Blower & Vigil Mechanism Policy approved by the Board has been implemented and no personnel have been denied access for making disclosure or report under the Policy to the Vigilance Officer and/or Audit Committee.

d. Company has not raised any funds through Preferential Allotment or Qualified Institutional Placement under Regulation 32(7A) of SEBI (LODR) 2015

e. Details of compliance with mandatory requirements and adoption of the non-mandatory requirements:

The Company has fairly complied with all mandatory requirements of the Listing Regulation .The status of compliance with non-mandatory requirements of SEBI Listing Regulations are as detailed hereunder:

i. Audit Qualification – There are no qualifications in the statutory Audit Report.

f. Accounting Treatment

The Accounting Standards issued by The Institute of Chartered Accountants of India is followed by the Company and the Company has not adopted a treatment different from that prescribed by any Accounting Standard in the preparation of financial statements.

g. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

There were no complaints received during the Financial Year 2024-25

h. Risk Management

The Company has in place Risk Management Plan for each and every department. The company reviews the risk of each department on a regular basis. The company does not fall under top 1000 listed entities so need not constitute a risk management committee.

i. Insider Trading Policy

The code of conduct for prevention of Insider Trading, as suggested under the SEBI (Prohibition of Insider Trading) Regulations, 2015 has been introduced with effect from 15.05.2015. The Company Secretary has been designated as the Compliance Officer for this purpose. The Board monitors the adherence to the various requirements as set out in the code. No violation of the code has taken place during the year.

j. CEO / CFO Certification

Pursuant to the provisions of Regulation 17(8) read with part B of the Schedule II of the Listing Regulations with the Stock Exchanges, the Chief Executive Officer(CEO) and Chief Financial Officer (CFO) have issued a Certificate to the Board as required for the Financial Year ended 31st March 2025. The Executive Director and the Chief Financial Officer of the Company also gives quarterly certification on financial results while placing the financial results before the Board in terms of Regulation 33(2) of Listing Regulations.

k. Code of Conduct

The Company's Board has laid down code of conduct for the employees at all levels including Senior Management and Directors of the Company. All Board Members and Senior Management Personnel have affirmed compliance with the code of conduct.

I. Compliance with Corporate Governance Norms

The Company has complied with all the mandatory requirements of Corporate Governance norms as specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46.

m. Management

The Management Discussion and Analysis Report forms a part of the Directors' Report.

n. Declaration by the Chairman and Managing Director with regards to adherence to the Code of Conduct

To The Members of Lotus Eye Hospital & Institute Limited

In accordance with Regulation 26 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 with the Stock Exchanges, I hereby confirm that, all the Directors and the Senior Management personnel including me, have affirmed compliance to their respective Codes of Conduct, as applicable for the Financial Year ended 31st March, 2025.

o. Demat Suspense Account/Unclaimed Suspense Account

No suspense account was created during the financial year 2024-25

Place: Coimbatore

Date :29.05.2025

For and on behalf of the Board

(Sd.)

Sangeetha Sundaramoorthy
Managing Director

CEO/ CFO CERTIFICATE

As required by Regulation 17(8) read with part B of the Schedule II of the Listing Regulations

We hereby certify that:

- a) We have reviewed the financial statements for the year ended 31st March 2025 and that to the best of our knowledge and belief:
 - i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 - ii. these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b) There are, to the best of our knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violate any of the company's code of conduct.
- c) We accept the responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which they are aware and the steps they have taken or propose to take to rectify these deficiencies.
- d) We have indicated to the auditors and the audit committee that there are no:
 - I. significant changes in internal control over financial reporting during the year;
 - II. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - III. instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

For and on behalf of the Board

Sd/

KS Ramalingam
Chief Executive Officer

Sd/

Reghunathan Ramanujam
Chief Financial officer

CORPORATE GOVERNANCE COMPLIANCE CERTIFICATE

To

The Members of Lotus Eye Hospital and Institute Limited
(CIN: L85110TZ1997PLC007783)
SF No.770/12, Avanashi Road,
Civil Aerodrome Post,
Coimbatore – 641014

I have examined all the relevant records of **Lotus Eye Hospital and Institute Limited** ("hereinafter called as the "Company") for the purpose of certifying compliance with the conditions of Corporate Governance stipulated in Chapter IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial Year ended **31st March, 2025**. I have obtained all the information and explanations which to the best of my knowledge and belief were necessary for the purpose of certification.

The compliance with the conditions of Corporate Governance is the responsibility of the Management. My examination was limited to the procedure and implementation process adopted by the Company for ensuring compliance with the conditions of Corporate Governance.

This certificate is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

In my opinion and to the best of my information and according to the explanations given to me, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

P. ESWARAMOORTHY AND COMPANY
Company Secretaries

Place: Coimbatore
Date: 29.05.2025
UDIN: F006510G000481490
Peer review Cert. No.933/2020

P. Eswaramoorthy
Proprietor
FCS No.: 6510, CP No.: 7069

(Under regulation 34(3) read with Schedule V Para C Sub clause (10)(i) of the **Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**)

To
The Members of Lotus Eye Hospital and Institute Limited
(CIN: L85110TZ1997PLC007783)
SF No.770/12,Avanashi Road,
Civil Aerodrome Post,
Coimbatore – 641014

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Lotus Eye Hospital and Institute Limited having CIN: L85110TZ1997PLC007783 and having registered office at SF No.770/12,Avanashi Road, Civil Aerodrome Post, Coimbatore – 641014 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2025 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sl. No.	DIN/DPIN/PAN	Full Name	Designation	Date of Appointment
1	01859252	SUNDARAMOORTHY SANGEETHA	Managing Director	14/11/2019
2	02050806	SUNDARAMOORTHY KAVETHA	Director	30/05/2016
3	01016571	KUTTAPALAYAM RAMALINGAM SONGAPPAN	Whole time Director	10/02/2021
4	09012904	SENGODAGOUNDER NATESAN	Director	02/01/2021
5	07097588	GOPALAKRISHNAN KARTHIK VEERAMANI	Director	21/12/2022
6	06680557	PERUMALSWAMY MAHENDRAN	Director	13/02/2023



Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

P. ESWARAMOORTHY AND COMPANY
Company Secretaries

P. Eswaramoorthy
Proprietor
FCS No.: 6510, CP No.: 7069
Place: Coimbatore
Date: 29.05.2025
UDIN: F006510G000481545
Peer review Cert. No.933/2020

Management Discussion and Analysis Report

Industry Structure and Development:

The most populated country in the world has seen health care sector grow leaps and bounds. Eye care sector being a pivot of the health care sector has seen exponential growth during the 5 years. The financial year 2024-25 has seen an allocation of ₹87657 crores marking a 12.59% increase compared to the previous year. The advent of new technological innovation has further reduced the complexities involved in erstwhile eye care services and the sector is witnessing increased adoption of digital technologies like telemedicine and digital health solutions, particularly in rural and underserved areas, to improve accessibility and efficiency.

The financial year 2024-25 has seen a rampant increase in availability of health care services in rural areas and underserved areas because of digital innovation, skill initiatives and various healthcare schemes brought by both central and state government. This expansion has helped all those in penury to have access to affordable health care services.

Overall, the Indian healthcare sector is experiencing a period of growth and transformation, driven by increased government investment, technological advancements, and a growing emphasis on preventive care and digital health solutions.

Opportunities and Threats

The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well as private players.

The significant contribution of health care sector to the GDP and the increasing population has attracted the focus of investors considering the health care as an attractive investment platform where higher returns are assured in the years to come. The private equity and venture capital investments surpassing US\$ 1 billion in the first five months of FY24, marking a 220% increase from the previous year is a clear example of the confidence reposed on the health care sector.

The innovative trends that have insinuated their way into the Healthcare sector are:

- **Artificial Intelligence and Cloud**, innovation in the healthcare is nothing new, but what have revolutionized is the intrusion of Artificial Intelligence into the healthcare sector, which has turned heads all over and has become the new route to success for the healthcare industry.

- **Need for Transparency**, there has been an urgent need felt to include and interpolate more transparency in the working, adoption and disposal of the healthcare companies, the awareness and the need of knowledge amongst the consumers have enforced the law makers to develop and instigate laws that proclaim and bring forward more transparent way of working amongst the industry.

Increase in Competitive intensity due to new entrants, Increased cost of resources, discontinuation of leases, lower contribution by the Government etc. are some major threats associated to the healthcare industries.

A significant shortage of ophthalmologists, particularly in rural areas, remains a challenge, highlighting the need for increased training and a more equitable distribution of eye care professionals.

Segment-wise or product-wise performance

Your Company operates in only one segment i.e. Eye Care and Related Activities.

Sector Outlook

The Indian eye care sector is experiencing significant growth, driven by factors like rising awareness of eye health, increasing incidence of vision-related disorders, and the growing availability of affordable eye care products and services. The market is expected to expand from USD 2,409.90 million in 2024 to USD 3,081.79 million by 2033, with a projected CAGR of 2.80% from 2025-2033.

Increased internet access and digital penetration are creating opportunities for the growth of over-the-counter (OTC) eye care products and services, particularly in urban areas.

The Indian eye care sector is poised for continued growth, with opportunities for both established players and new entrants. Addressing the challenges related to workforce shortages and access to care will be crucial for realizing the full potential of the market and ensuring that eye care services are available to all segments of the population.

Risk and Concerns

I. Competition:

The competition from the un-organized sector would be met by delivering quality eye care services at par with international standards which the un-organized sector lacks in view of constraints in investment to create a quality eye hospital.



Because of increased opportunities, many private players are entering into this sector. Your Company can counter this challenge by providing focused eye care delivery and by deploying the state of the art equipments backed by panel of expert Doctors.

ii. Shortage of skilled manpower:

Increasing demand for health care services combined with the aggressive expansion by the Indian private health care players is expected to significantly increase the demand for medical professionals. Similarly there is a shortage of medical and para-medical staff. We have a talented and skilled manpower in terms of Doctors, Nurses and para-medical staff. We continue to attract talented and skilled medical professionals.

iii. Investment:

The health care sector is a capital intensive sector and need significant funding to grow.

iv. Regulatory Risk

The evolution of the global regulatory environment has resulted in increased regulatory scrutiny that has raised the minimum standards to be maintained. This signifies the alignment of corporate performance objectives, while ensuring compliance with regulatory requirements.

v. Increased cost of resources

Failure to acquire resources at fair and reasonable rates and increase in operating expenses may impact the Company's growth and financials.

Internal control systems and their adequacy

Your company has established internal control systems to ensure optimum use in protecting its resources and ensuring adherence to its policies, procedures and statutes. There is proper and adequate system of internal control for the company and its branches. The company has appointed Internal Auditor to review the adequacy of the internal control system, procedures and policies. The internal auditor evaluates the adequacy of the internal control systems by testing the control mechanism and gives their recommendations to the management.

Discussion on financial performance with respect to operational performance

Financial performance with respect to operational performance has been dealt with in the Directors' Report which should be treated as forming part of this Management Discussion and Analysis Report.

Material developments in Human Resources / Industrial Relations front, including number of people employed.

There were 348 numbers of permanent employees on the rolls of the Company as on 31.03.2025. During the year under review, your company enjoyed cordial relationship with the employees at all levels.

Cautionary Statement

The Management Discussion and Analysis Report contains forward looking statements based upon the data available with the Company, assumptions with regard to global economic conditions, the government policies etc. Actual results might differ materially from those either expressed or implied.

For and on behalf of the Board

Place: Coimbatore

Date: 29.05.2025

(sd)
Sangeetha Sundaramoorthy
Managing Director

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2025

[Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To

The Members

Lotus Eye Hospital and Institute Limited

[CIN: L85110TZ1997PLC007783]

SF No.770/12, Avanashi Road,

Civil Aerodrome Post,

Coimbatore – 641 014

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Lotus Eye Hospital and Institute Limited** (hereinafter called “the Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company has, during the Audit period covering the Financial Year ended **31st March, 2025**, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period ended 31st March, 2025 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

- 
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
 - (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 [Not applicable as the Company has not issued any security during the Financial Year under review];
 - d. The Securities and Exchange Board of India (Share based Employee benefits) Regulations, 2014 [Not applicable as the Company does not have any Scheme for share based employee benefits during the Financial Year under review];
 - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 [Not applicable as the Company has not issued and listed any debt securities during the Financial Year under review];
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client [Not applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the Financial Year under review];
 - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 [Not applicable as the Equity Shares of the Company have not been delisted during the Financial Year under review];
 - h. The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 [Not applicable as the Company has not bought back / proposed to buy back any of its securities during the Financial Year under review]
 - i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 

- 
- (vi) Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

I have relied on the representation made by the Company and its officers, relating to systems and mechanisms framed by the Company, for ensuring compliance with the other Laws and Regulations as applicable to the Company.

I have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with BSE Limited and National Stock Exchange of India Limited.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, and Standards wherever applicable.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate Notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance and with shorter notice wherever required, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

I am informed that there were no dissenting members, on any of the matters, discussed at the Board Meetings during the Financial Year under review, whose views were required to be captured and recorded as part of the minutes.

I further report that based on the information provided by the Company, its officers and authorized representatives during the conduct of the audit and on the review of the quarterly compliance reports submitted by the respective department heads and the Company Secretary which is taken on record by the Board of Directors at their meeting(s), I am of the opinion that there are adequate systems and processes in place in the Company which is commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.



I further report that during the period covered under the Audit, the Company has not made any specific events / actions having a major bearing on the Company's affairs in pursuance of laws, rules, regulations and guidelines referred to above.

P. ESWARAMOORTHY AND COMPANY
Company Secretaries

Place: Coimbatore
Date: 29.05.2025
UDIN: F006510G000481413
Peer review Cert. No.933/2020

P. Eswaramoorthy
Proprietor
FCS No.: 6510, CP No.: 7069

ANNEXURE TO SECRETARIAL AUDIT REPORT OF EVEN DATE ISSUED BY COMPANY SECRETARY IN PRACTICE

To

The Members
Lotus Eye Hospital and Institute Limited
[CIN: L85110TZ1997PLC007783]
SF No.770/12, Avanashi Road,
Civil Aerodrome Post,
Coimbatore – 641 014

My Secretarial Audit Report of even date is to be read along with this letter.

1. Maintenance of Secretarial Records, devising proper system to ensure compliance with the provisions of all applicable laws and regulations and ensuring that systems are adequate and operate effectively, are the responsibilities of the Management of the Company. My responsibility is to express an opinion on these Secretarial Records based on Audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial Records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, I have obtained the Management's representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. My examination was limited to the verification of procedures on a test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

P. ESWARAMOORTHY AND COMPANY
Company Secretaries

Place: Coimbatore
Date: 29.05.2025
UDIN: F006510G000481413

P. Eswaramoorthy
Proprietor
FCS No.: 6510, CP No.: 7069



Independent Auditor's Report:

To the Members of Lotus Eye Hospital and Institute Limited Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Lotus Eye Hospital and Institute Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended and notes to the financial statements including a summary of the material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, the profit including other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and informing our opinion thereon and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matter	How the matter was addressed in our audit
Evaluation of uncertain tax positions	
The Company operates in multiple jurisdictions and is subject to periodic challenges by local tax authorities on arrangement of tax matters during the normal course of business including direct & indirect tax matters and forum. These involve significant management judgment to determine the possible outcome of the uncertain tax positions, consequently having an impact on related accounting and disclosures in the financial statements. (Refer Note no. 44 to the financial statements)	Our audit procedures include the following substantive procedures: • Obtained understanding of key uncertain tax positions; • Read and analyzed select key correspondences including responses to the tax authorities; • Discussed with appropriate senior management and evaluated management's underlying key assumptions in estimating the tax provisions and the possible outcome of the disputed cases. We agreed with the management's evaluation.

Information Other than the Financial Statements and Auditor's Report There on

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report but does not include the financial statements and our auditor's report there on.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion there on.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India.



This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safe guarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for over seeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- 
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - (d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - (e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in; (i) planning the scope of our audit work and in evaluating the result of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of section 143 (11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this report are in agreement with the books of account;
 - d. In our opinion, the afore said financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules 2014;
 - e. On the basis of the written representations received from the directors as on March 31, 2025 and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164(2) of the Act;
 - f. With respect to the adequacy of the internal financial controls over financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

- 
- g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2021, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements [Refer Note no: 44 to the Financial Statements].
 - ii. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented, that, to the best of its knowledge and belief as disclosed in Note No. 43(viii) to the financial statements no funds (which are material either individually or in aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- 
- g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2021, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements [Refer Note no: 44 to the Financial Statements].
 - ii. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented, that, to the best of its knowledge and belief as disclosed in Note No. 43(viii) to the financial statements no funds (which are material either individually or in aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief as disclosed in Note No. 43(viii) to the financial statements no funds (which are material either individually or in aggregate) have been received by the Company from any person or entity, including foreign entities ("Funding parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



- (c) Based on such audit procedures we have considered reasonable and appropriate in the circumstances; nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. (a) The Company has not declared or paid any final dividend during the previous year.
(b) The Company has not declared or paid any interim dividend during the year.
(c) The Board of Directors have not recommended any final dividend for the financial year ended 31st March, 2025.
- vi. Based on our examination which included test checks, the company has used accounting software for maintaining its books of account for the financial year ended March 31, 2025, which has the feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trial feature being tampered with and the audit trial has been preserved by the Company as per the statutory requirements for record retention.

For **Anbarasu and Jalapathi**
Chartered Accountants Firm
Registration No.:010795S

(sd.) **CA. K. Jalapathi**
Partner
Coimbatore, Membership No.:214823
May 29, 2025. **UDIN**:25214823BMUKAG5697





Annexure “A” to the Independent Auditor Report

(Referred to in Paragraph 1 under ‘Report on Other Legal and Regulatory Requirements’ in the Independent Auditor’s Report of even date to the members of Lotus Eye Hospital and Institute Limited on the financial statements for the year ended March 31, 2025)

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

(i) a. (A) The Company is in the process of updating its records showing full particulars, including quantitative details and situation of Property, Plant and Equipment. However, an item wise list of Property, Plant and Equipment (including right of use asset) containing the particulars for calculation of depreciation is maintained.

(B) The Company is in the process of updating its records showing full particulars and details of intangible assets. However, an item wise list of intangible assets containing the particulars for calculation of amortization is maintained.

b. All Property, Plant and Equipment have not been physically verified by the management during the year but there is a phased program of verification based on the item wise list maintained for computation of depreciation which, in our opinion, needs to be strengthened having regard to the size of the company and nature of its assets. As explained to us, no material discrepancies were noticed on such verification. However, in the absence of complete information in fixed asset register as stated in clause (a) above, we are unable to comment on the discrepancies.

c. Based on the examination of title deeds provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee), disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

d. The Company has not re valued any of its Property, Plant and Equipment (including right-to-use assets) and intangible assets during the year.

e. No such proceedings have been initiated during the year or are pending against the Company as at March 31, 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988, as amended, and rules made there under.

(ii) a. As explained to us, the management has conducted physical verification of inventory at reasonable intervals and in our opinion, the coverage and procedure of such verification by the management is appropriate; Discrepancies of 10% or more were not noticed.

- b. The Company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, at any point of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
- (iii) According to the information and explanations given to us , during the year the Company has not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnerships or any other parties. Accordingly, reporting under clause 3(iii)(a) to (f) of the Order is not applicable to the company.
- (iv) According to the information and explanations given to us, the Company has not granted any loans, made investments, provided any guarantee or security to company covered under section 185 and 186 and hence reporting under clause 3(iv) of the Order is not applicable to the company.
- (v) According to the information and explanations given to us, the Company has not accepted any deposits covered under Section 73 to 76 of the Act. Accordingly, paragraph 3(v) of the Order is not applicable to the company.
- (vi) We have broadly reviewed the cost records maintained by the company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended prescribed by the Central Government under section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii) (a) According to the information and explanations provided to us, the company has generally been regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, service tax, value added tax, goods and service tax, customs duty, excise duty, cess and any other material statutory dues applicable to it with the appropriate authorities.
- (b) As explained to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income tax, sales tax, service tax, value added tax, goods and service tax, customs duty, excise duty, cess and any other material statutory dues applicable to it, were outstanding, at the year end, for a period of more than six months from the date they became payable.
- (c) Detail so dues which have not been deposited as on March 31, 2025 on account of disputes are given below:

Name of Statue	Nature of dues	Forum where Dispute is Pending	Period to which the Amount Relates	Amount (Rs.in lakhs)
Income Tax Act, 1961	Income Tax	Commissioner of Income tax (Appeals), Coimbatore	2016-17	55.40
Kerala Value Added Tax Act, 2003	Value Added tax	High Court of Kerala	2011-12	21.61
Kerala Value Added Tax Act, 2003	Value Added Tax	Kerala Value Added Tax Appellate Tribunal	2013-14	5.16
Employees' State Insurance Act, 1948	Employees' State Insurance	Labour Court, Salem	2014-19	6.95

(viii) According to the information and explanations given to us, there were no transactions relating to unrecorded income that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(ix) According to the information and explanations given to us,

- a. The Company has not taken any loans or other borrowings from any lender. Hence reporting under clause 3(ix)(a) of the Order is not applicable.
- b. The Company has not been declared wilful defaulter by any bank or financial institution or other lender.
- c. The Company has not taken any term loan during the year and there are no outstanding term loans at the beginning of the year and hence, reporting under clause 3(ix)(c) of the Order is not applicable.
- d. On an overall examination of the financial statements of the Company, the Company has not raised any funds on short term basis and hence, reporting under clause 3(ix)(d) of the Order is not applicable.
- e. The Company does not have any investments in subsidiaries, associates or joint ventures and hence, reporting under clause 3(ix)(e) of the Order is not applicable.
- f. The Company does not have any investments in subsidiaries, associates or joint ventures and hence, reporting under clause 3(ix)(f) of the Order is not applicable.

(viii) According to the information and explanations given to us, there were no transactions relating to unrecorded income that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(ix) According to the information and explanations given to us,

- a. The Company has not taken any loans or other borrowings from any lender. Hence reporting under clause 3(ix)(a) of the Order is not applicable.
- b. The Company has not been declared wilful defaulter by any bank or financial institution or other lender.
- c. The Company has not taken any term loan during the year and there are no outstanding term loans at the beginning of the year and hence, reporting under clause 3(ix)(c) of the Order is not applicable.
- d. On an overall examination of the financial statements of the Company, the Company has not raised any funds on short term basis and hence, reporting under clause 3(ix)(d) of the Order is not applicable.
- e. The Company does not have any investments in subsidiaries, associates or joint ventures and hence, reporting under clause 3(ix)(e) of the Order is not applicable.
- f. The Company does not have any investments in subsidiaries, associates or joint ventures and hence, reporting under clause 3(ix)(f) of the Order is not applicable.

(x) According to the information and explanations given to us,

- a. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
- b. the company has not made any prefer entail allotment or private placement of shares or convertible debentures (fully or partly or optionally) during the year and hence reporting under clause 3(x)(b) of the Order is not applicable.

(xi) a. To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company and no material fraud on the Company by its officers or employees has been noticed or reported during the year.

b. No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

c. To the best of our knowledge and according to the information and explanations given to us, no whistle-blower complaints have been received by the company during the year and hence reporting under clause 3(xi)(c) of the Order is not applicable.

- 
- (xii) The Company is not a Nidhi Company and hence reporting under clause 3(xii) of the Order is not applicable to the company.
- (xiii) In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable Indian accounting standards.
- (xiv) a. In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- b. We have considered the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- (xv) In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its directors or persons connected with them and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the company.
- (xvi) a. In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
- b. In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and according lyre porting under clause 3(xvi)(d) of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx)(a) In respect of other than on-going projects, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII of the Companies Act (the Act), in compliance with second proviso to sub section 5 of section 135 of the Act.

(b) In respect of ongoing projects, the Company has transferred the unspent amount to a special account, within a period of thirty days from the end of the financial year in compliance with Section 135(6) of the said Act. This matter has been disclosed in note no.41 to the financial statements.

Financial year	Amount unspent on CSR activities for Ongoing Projects (In Lakhs)	Amount transferred to Special Account within 30 days from the end of the Financial Year (In Lakhs)	Amount Transferred after the due date (In Lakhs)	Date of Transfer
FY 2023-2024	7.28	7.28	-	30-04-2024

(xxi) The Company has no subsidiary and hence Clause 3(xxi) is not applicable.

For **Anbarasu and Jalapathi**
Chartered Accountants
Firm Registration No.:010795S

Coimbatore, May 29, 2025.
(sd.)

CA.K. Jalapathi
Partner
Membership No.:214823
UDIN:25214823BMUKAG5697

Annexure “B” to the Independent Auditors’ Report

(Referred to in paragraph 2(f) under ‘Report on Other Legal and Regulatory Requirements’ in the Independent Auditor’s Report of even date to the members of Lotus Eye Hospital and Institute Limited on the audit of financial statements for the year ended March 31, 2025)

Report on the Internal Financial Controls with reference to Financial Statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls with reference to financial statements of Lotus Eye Hospital and Institute Limited (“the Company”) as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibilities for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls with reference to financial statements based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (the Act).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing specified under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.



The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.

Meaning of Internal Financial Controls with reference to financial statements

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditure of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2025, based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For Anbarasu and Jalapathi

Chartered Accountants

Firm Registration No.: 0107955

Coimbatore, May 29, 2025

(sd.)

CA. K. Jalapathi

Partner

Membership No.: 214823

UDIN: 25214823BMUKAG5697

SECRETARIAL AUDIT REPORT**FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2025**

[Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To

The Members

Lotus Eye Hospital and Institute Limited

[CIN: L85110TZ1997PLC007783]

SF No.770/12, Avanashi Road,

Civil Aerodrome Post,

Coimbatore – 641 014

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Lotus Eye Hospital and Institute Limited** (hereinafter called “the Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company has, during the Audit period covering the Financial Year ended **31st March, 2025**, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period ended 31st March, 2025 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

- 
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
 - (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 [Not applicable as the Company has not issued any security during the Financial Year under review];
 - d. The Securities and Exchange Board of India (Share based Employee benefits) Regulations, 2014 [Not applicable as the Company does not have any Scheme for share based employee benefits during the Financial Year under review];
 - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 [Not applicable as the Company has not issued and listed any debt securities during the Financial Year under review];
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client [Not applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the Financial Year under review];
 - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 [Not applicable as the Equity Shares of the Company have not been delisted during the Financial Year under review];
 - h. The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 [Not applicable as the Company has not bought back / proposed to buy back any of its securities during the Financial Year under review];
 - i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 



(vi) Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

I have relied on the representation made by the Company and its officers, relating to systems and mechanisms framed by the Company, for ensuring compliance with the other Laws and Regulations as applicable to the Company.

I have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (i) The Listing Agreements entered into by the Company with BSE Limited and National Stock Exchange of India Limited.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, and Standards wherever applicable.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate Notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance and with shorter notice wherever required, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

I am informed that there were no dissenting members, on any of the matters, discussed at the Board Meetings during the Financial Year under review, whose views were required to be captured and recorded as part of the minutes.

I further report that based on the information provided by the Company, its officers and authorized representatives during the conduct of the audit and on the review of the quarterly compliance reports submitted by the respective department heads and the Company Secretary which is taken on record by the Board of Directors at their meeting(s), I am of the opinion that there are adequate systems and processes in place in the Company which is commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.



I further report that during the period covered under the Audit, the Company has not made any specific events / actions having a major bearing on the Company's affairs in pursuance of laws, rules, regulations and guidelines referred to above.

P. ESWARAMOORTHY AND COMPANY

Company Secretaries

Place: Coimbatore

Date: 29.05.2025

UDIN: F006510G000481413

Peer review Cert. No.933/2020

P. Eswaramoorthy

Proprietor

FCS No.: 6510, CP No.: 7069

ANNEXURE TO SECRETARIAL AUDIT REPORT OF EVEN DATE ISSUED BY COMPANY SECRETARY IN PRACTICE

To
The Members
Lotus Eye Hospital and Institute Limited
[CIN: L85110TZ1997PLC007783]
SF No.770/12, Avanashi Road,
Civil Aerodrome Post,
Coimbatore – 641 014

My Secretarial Audit Report of even date is to be read along with this letter.

1. Maintenance of Secretarial Records, devising proper system to ensure compliance with the provisions of all applicable laws and regulations and ensuring that systems are adequate and operate effectively, are the responsibilities of the Management of the Company. My responsibility is to express an opinion on these Secretarial Records based on Audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial Records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, I have obtained the Management's representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. My examination was limited to the verification of procedures on a test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

P. ESWARAMOORTHY AND COMPANY
Company Secretaries

Place: Coimbatore
Date: 29.05.2025
UDIN: F006510G000481413
Peer review Cert. No.933/2020

P. Eswaramoorthy
Proprietor
FCS No.: 6510, CP No.: 7069

Lotus Eye Hospital and Institute Limited
CIN: L85110TZ1997PLC007783

Balance Sheet

(Amount in Rs. Lakhs)

Particulars	Note	As at March 31, 2025	As at March 31, 2024
Assets			
1. Non-current assets			
(a) Property, plant and equipment	2	4,874.18	4,587.35
(b) Right of use asset	3	520.04	270.32
(c) Capital work in progress	4	-	7.73
(d) Intangible assets	5	12.96	7.44
(e) Financial assets			
(i) Other financial assets	6	238.78	235.16
(f) Deferred tax assets (net)	7	8.16	30.45
(g) Other non-current assets	8	146.24	122.51
Total Non-current assets (A)		5,800.36	5,260.96
2. Current assets			
(a) Inventories	9	382.96	321.16
(b) Financial assets			
(i) Trade receivables	10	132.30	125.78
(ii) Cash and cash equivalents	11	201.11	265.26
(iii) Bank balances other than (ii) above	12	213.97	438.78
(c) Other current assets	13	226.67	250.73
Total Current assets (B)		1,157.01	1,401.71
Total Assets (A + B)		6,957.37	6,662.67
Equity and Liabilities			
1. Equity			
(a) Equity share capital	14	2,079.63	2,079.63
(b) Other equity	15	3,920.40	3,861.29
Total Equity (C)		6,000.03	5,940.92
2. Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Lease Liabilities	16	202.67	68.86
(ii) Trade payables			
(1) Dues to Others	17	-	7.68
(iii) Other Financial Liabilities	18	12.21	11.44
Total Non-current liabilities (D)		214.88	87.98
Current liabilities			
(a) Financial liabilities			
(i) Lease Liabilities	19	140.35	42.18
(ii) Trade payables	20		
(1) Dues to micro and small enterprises.		54.71	21.28
(2) Dues to Others		281.58	324.40
(iii) Other Financial Liabilities	21	182.45	163.88
(b) Other current liabilities	22	71.72	82.03
(c) Provisions	23	11.65	-
Total Current liabilities (E)		742.46	633.77
Total Liabilities (D+E)		957.34	721.75
Total Equity and Liabilities (C+D+E)		6,957.37	6,662.67

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For Anbarasu and Jalapathi

Chartered Accountants

Firm Registration No.: 010795S

(sd.) CA. K. Jalapathi

Partner

Membership no: 214823

Coimbatore,
May 29, 2025.

For and on behalf of the Board of Directors of

Lotus Eye Hospital and Institute Limited

(sd.) Ms. S.Sangeetha

Managing Director

DIN: 01859252

(sd.) CA Perumalsamy

Mahendran

Director

DIN:06680557

(sd.) Mr. Senagounder Natesan

Director

DIN: 09012904

(sd.) Dr. K S Ramalingam

Chief Executive Officer,

Executive director

DIN: 01016571

(sd.) CA Reghunathan Ramanuj

Chief Financial Officer

(sd.) CS Achuth Menon

Company Secretary

Statement of Profit and Loss

(Amount in Rs. Lakhs)

Sr. No	Particulars	Note	For the year ended March 31, 2025	For the year ended March 31, 2024
I. Income				
(a) Revenue from operations	24		4,956.25	4,820.99
(b) Other income	25		130.13	130.27
Total income (I)			5,086.38	4,951.26
II. Expenses				
(a) Cost of materials consumed	26		823.63	844.23
(b) Purchases of stock-in-trade	27		740.44	705.05
(c) Changes in inventories	28		(18.36)	(17.18)
(d) Service expenses	29		944.60	761.14
(e) Employee benefits expense	30		1,161.21	981.01
(f) Finance costs	31		35.50	9.74
(g) Depreciation and amortization expense	32		300.68	372.78
(h) Other expenses	33		961.40	893.71
Total expenses (II)			4,949.10	4,550.48
III. Profit before exceptional items and tax (I - II)			137.28	400.78
IV. Exceptional items	34		0.98	0.59
V. Profit before tax (III + IV)			138.26	401.37
VI. Tax expenses				
(a) Current tax	35		36.34	100.19
(b) Deferred tax	35		27.99	9.73
			64.33	109.92
VII. Profit for the period (V - VI)			73.93	291.45
VIII. Other comprehensive income				
A. Items that will not be reclassified to profit or loss				
- Re-measurements of the defined benefit plans			(20.53)	(6.22)
- Income tax on the above item			5.71	1.73
B. Items that will be reclassified to profit or loss			-	-
Total other comprehensive income (VIII)			(14.82)	(4.49)
Total comprehensive income for the period (VII + VIII)			59.11	286.96
Earnings per equity share (Nominal value of share of Rs. 10 each)				
Basic and diluted (in Rs.)	39		0.36	1.40

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For Anbarasu and Jalapathi
Chartered Accountants
Firm Registration No.: 010795S

(sd.) CA. K. Jalapathi
Partner
Membership no: 214823

For and on behalf of the Board of Directors of
Lotus Eye Hospital and Institute Limited

(sd.) Ms. S.Sangeetha
Managing Director
DIN: 01859252

(sd.) CA Perumalsamy
Mahendran
Director
DIN:06680557

(sd.) Mr. Senagounder Natesan
Director
DIN: 09012904

(sd.) Dr. K S Ramalingam
Chief Executive Officer,
Executive director
DIN: 01016571

Coimbatore,
May 29, 2025.

(sd.) CA Reghunathan Ramanujam
Chief Financial Officer

(sd.) CS Achuth Menon
Company Secretary

Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Statement of Cash Flows

(Amount in Rs. Lakhs)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
A.Cash flows from operating activities		
Profit before tax and exceptional item	137.28	400.79
<i>Adjustments:</i>		
Depreciation and amortisation	300.68	372.78
Interest income	(35.81)	(49.75)
Rental income	(43.95)	(43.95)
Finance costs	35.50	9.74
Operating cash flow before working capital changes	393.70	689.61
Change in operating assets & liabilities :		
Inventories	(61.80)	(42.10)
Trade receivables	(6.51)	(8.57)
Other assets (current and non-current)	22.90	(52.79)
Trade payables	(17.07)	38.36
Provisions	(8.88)	(6.22)
Other liabilities (current and non-current)	10.11	75.76
Cash generated from operating activities	332.45	694.05
Taxes paid (Net)	(62.54)	(125.71)
Net cash generated from operating activities (A)	269.91	568.34
B.Cash flows from investing activities		
Purchase of property, plant and equipment	(482.72)	(556.58)
Capital Work in Progress	-	(7.73)
Proceeds from the sale of property, plant and equipment	3.75	7.34
Increase/ (Decrease) in Bank balances not considered as Cash and cash equivalents	-	95.00
Interest income	35.81	49.75
Rental income	43.95	43.95
Net cash generated from / (used in) investing activities (B)	(399.21)	(368.27)
C.Cash flows from financing activities		
Finance costs	(35.50)	(9.74)
Dividend paid	(1.07)	(101.23)
Payment of lease liabilities	(123.09)	(226.46)
Net cash (used in) / generated from financing activities (C)	(159.66)	(337.43)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(288.96)	(137.36)
Cash and Bank balance at the beginning of the year	704.04	841.40
Less: Bank Balances not considered as Cash & Cash equivalents as per	213.97	438.78
Cash and equivalents at the end of the year	201.11	265.26
Cash on hand	11.36	7.04
Balance with banks	189.75	258.22

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For Anbarasu and Jalapathi
Chartered Accountants
Firm Registration No.: 010795S

(sd.) CA. K. Jalapathi

Partner

Membership no: 214823

Coimbatore,
May 29, 2025.

For and on behalf of the Board of Directors of
Lotus Eye Hospital and Institute Limited

(sd.) Ms. S.Sangeetha

Managing
Director

DIN: 01859252

**(sd.) Mr. Senagounder
Natesan**

Director
DIN: 09012904

**(sd.) CA Reghunathan
Ramanujam**

Chief Financial
Officer

**(sd.) CA Perumalsamy
Mahendran**

Director

DIN:06680557

(sd.) Dr. K S Ramalingam

Chief Executive Officer,
Executive director
DIN: 01016571

(sd.) CS Achuth Menon

Company Secretary

Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Statement of changes in equity

A. Equity share capital

Particulars	(Amount in Rs. Lakhs)
Balance as at 1st April 2023	2,079.63
Changes in Equity share capital during the year	-
Balance as at 31st March 2024	2,079.63
Changes in Equity share capital during the year	-
Balance as at 31st March 2025	2,079.63

B. Other equity

Particulars	Reserves and Surplus			Items of Other Comprehensive Income (OCI)	Total
	Capital Reserve	Securities Premium	Retained Earnings	Remeasurement of post-employment benefit obligations	
Balance as at April 1,2023	-	2,514.14	1,169.45	(5.28)	3,678.31
Add: Profit for the year	-	-	291.45	-	291.45
Add: Other Comprehensive Income for the year (Net of taxes)	-	-	-	(4.49)	(4.49)
Less: Dividend	-	-	(103.98)	-	(103.98)
Balance as at March 31,2024	-	2,514.14	1,356.92	(9.77)	3,861.29
Add: Profit for the year	-	-	73.93	-	73.93
Add: Other Comprehensive Income for the year (Net of taxes)	-	-	-	(14.82)	(14.82)
Less: Dividend	-	-	-	-	-
Balance as at March 31, 2025	-	2,514.14	1,430.85	(24.59)	3,920.40

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For Anbarasu and Jalapathi

Chartered Accountants

Firm Registration No.: 010795S

(sd.) CA. K. Jalapathi

Partner

Membership no: 214823

For and on behalf of the Board of Directors of

Lotus Eye Hospital and Institute Limited

(sd.) Ms. S.Sangeetha

Managing Director

DIN: 01859252

(sd.) CA Perumalsamy Mahendran

Director

DIN:06680557

(sd.) Mr. Senagounder Natesan

Director

DIN: 09012904

(sd.) Dr. K S Ramalingam

Chief Executive Officer,

Executive director

DIN: 01016571

Coimbatore,
May 29, 2025.

(sd.) CA Reghunathan Ramanujam

Chief Financial Officer

(sd.) CS Achuth Menon

Company Secretary

Note 1:

A. Corporate Information

The company was incorporated as “Kalaivani Health Centre Pvt Ltd” on 14 March 1997 as a private limited company under the Companies Act, 1956. The name of the company was changed to “Lotus Eye Care Hospital Pvt Ltd” on 23 January 2001 and later on the company was converted into Public Limited Company on 16 October 2007 and subsequently the name was changed to “Lotus Eye Hospital and Institute Limited” on 12 April 2013. The Company has its registered office at Coimbatore, India. CIN of the Company is L85110TZ1997PLC007783.

The Company is engaged in the field of ophthalmology (Eye) and its related operations. The Company has seven branches in Tamil Nadu in SITRA (Coimbatore), R.S. Puram (Coimbatore), Saravanampatty (Coimbatore), Mettupalayam, Tirupur, Salem and Karur and two branches in Kerala in Kadavanthra (Kochi) and Mulanthuruthy (Ernakulam). The Company’s equity shares are listed from 03 August 2008 on Bombay Stock Exchange Ltd and National Stock Exchange of India Ltd, Mumbai.

B. Material Accounting Policy Information

These financial statements of the Company have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the ‘Ind AS’) as notified by Ministry of Corporate Affairs (‘MCA’) under Section 133 of the Companies Act, 2013 (‘the Act’) read with the Companies (Indian Accounting Standards) Rules, 2015, as amended and other relevant provisions of the Act. The Company has uniformly applied the accounting policies during the periods presented.

Specific disclosure of material accounting policy information where Ind AS permits options is made hereunder:

The company has assessed the materiality of the accounting policy information, which involves exercising judgement and considering both quantitative and qualitative factors by taking into account not only the size and nature of the item or condition but also the characteristics of the transactions, events or conditions that could make the information more likely to impact the decisions of the users of the financial statements.

1.1 Basis for preparation

The financial statements have been prepared on going concern basis in accordance with accounting principles generally accepted in India. The presentation of financial statement is based on Ind AS Schedule III of the Companies Act, 2013.

The financial statements have been prepared on the historical cost basis except for the following material items in the Balance sheet.

- (i) Financial assets are measured either at fair value or at amortised cost depending on their classification;
- (ii) Employee defined benefit assets/ liabilities are recognised as the net total of fair value of plan assets, adjusted for actuarial gains/losses and the present value of defined benefit obligations.

(iii) Right of use of assets are recognised at the present value of future lease payments and depreciated on a straight line basis based on the lease term of the asset.

Historical cost is generally based on fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these financial statements is determined on such a basis, except for leasing transactions that are within the scope of Ind AS 116 and measurements that have some similarities to fair value but are not fair value, such as net realizable value in Ind AS 2 or value in use in Ind AS 36.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

Level 1 - inputs are quoted prices (unadjusted) in active markets for identical assets and liabilities that the entity can access at the measurement date.

Level 2 - inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

Level 3 - inputs are unobservable inputs for the assets or liabilities.

The Company's Financial Statements are presented in Indian Rupees, which is rounded to the nearest lakhs except when otherwise stated.

1.2 Current and non-current classification

For the purpose of Current / Non-Current classification, the Company has reckoned its normal operating cycle as twelve months based on the nature of products/ activities of the company and the time between the acquisition of assets or inventories for processing and their realisation in cash and cash equivalents.

1.3 Key Accounting estimates and judgments

(i) Use of Estimates

The preparation of financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates.

(ii) Changes in estimates

The estimates and underlying assumptions are reviewed on an ongoing basis. The effect of change in an accounting estimate is recognized prospectively by including it in profit or loss (a) In the period of the change if the change affects only that period; or (b) the period of the change and future periods, if the change affects both.



However, the change in an accounting estimate that gives rise to changes in assets and liabilities, or relates to an item of equity, is recognized by adjusting the carrying amount of the related asset, liability or equity item in the period of the change.

(iii) Key sources of estimation uncertainty

Key assumption concerning the future, and other key sources of estimation uncertainty at the end of the reporting period that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year is as given below.

(a) Actuarial valuation

The determination of Company's liability towards defined benefit obligation to employees is made through independent actuarial valuation including determination of amounts to be recognised in the Statement of Profit and Loss and in Other Comprehensive Income. Such valuation depends upon assumptions determined after taking into account inflation, seniority, promotion and other relevant factors such as supply and demand factors in the employment market. Information about such valuation is provided in the Notes to the financial statements.

(b) Claims, Provisions and Contingent Liabilities

The Company has ongoing discussions/litigations with various tax and regulatory authorities and third parties. Where an outflow of funds is believed to be probable and a reliable estimate of the outcome of the dispute can be made based on management's assessment of specific circumstances of each dispute and relevant external advice, management provides for its best estimate of the liability. Such accruals are by nature complex and can take number of years to resolve and can involve estimation uncertainty. Information about such litigations if any, is provided in the Notes to the financial statements.

(c) Revenue Recognition

Revenue from fees charged for services rendered to insured and corporate patients are subject to approvals from the insurance companies and corporates. Accordingly, the Company estimates the amounts likely to be disregarded by such companies based on past trends. Estimations based on past trends are also required in determining the value of consideration from customers to be allocated to award credits for customers.

(d) Fair value measurements and valuation processes

Some of the Company's assets and liabilities are measured at fair value for financial reporting purposes.

In estimating the fair value of an asset or a liability, the Company uses market-observable data to the extent it is available. Where Level 1 inputs are not available, the Company engages third party qualified valuers to perform the valuation.

(e) Expected Credit Loss

The Company has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix considering the nature of receivables and the risk characteristics. The provision matrix takes into accounts historical credit loss experience and adjusted for forward looking information. The expected credit loss allowance is based on the ageing of the day of the receivables are due and the rates as given in the provision matrix.

1.4 Property, Plant and Equipment (PPE)

Items of Property, plant and equipment acquired or constructed are initially recognized at historical cost net of recoverable taxes, duties, trade discounts and rebates, less accumulated depreciation and impairment loss, if any. The historical cost of Property, plant and equipment comprises of its purchase price, borrowing costs and adjustment arising from exchange rate variations attributable to the assets, including any cost directly attributable to bringing the assets to their working condition for their intended use.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The Company identifies and determines cost of each component/part of the plant and equipment separately, if the component/part has a cost which is material to the total cost of the plant and equipment and has useful lives that is materially different from that of the remaining plant and equipment.

The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Statement of Profit and Loss during the year in which they are incurred. Gains and losses arising from derecognition of PPE are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized.

Depreciation methods, estimated useful lives and residual values

Depreciation on Property, Plant and Equipment is provided under straight line method (refer Note 2 for change in method of depreciation effective from 1st April 2024) at the rates determined based on Useful Lives of the respective assets and the residual values in accordance with Schedule II of the Companies Act, 2013.

Estimated useful lives of the assets are as follows:

Category of asset	Useful Life (in years)
Building	
(a) Freehold	60
(b) Improvements to Leasehold Building	Useful Life or Lease term whichever is lower
Plant & Machinery	10 & 5
Surgical Equipments	13
Furnitures & Fixtures	10
Office Equipments	10 & 5
Vehicles	8
Computer & Accessories	3 & 10

1.5 Intangible Assets

Intangible assets are recognized only if it is probable that future economic benefits that are attributable to the asset will flow to the enterprise and the cost of the asset can be measured reliably. Computer software licenses are capitalized on the basis of costs incurred to acquire and bring to use the specific software. Operating software is capitalized and amortized along with the related fixed asset. The useful life of the software is estimated to be 10 years.

1.6 Impairment of Assets

At the Balance Sheet date an assessment is done in accordance with Ind AS 36, to determine whether there is any indication of impairment in the carrying amount of the company's assets. An asset is treated impaired when carrying cost of assets exceeds its recoverable value.

An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss, if any, recognized in prior accounting period is reversed if there has been any change in the estimate of recoverable amount.

1.7 Inventories

Closing stock of pharmacy, canteen, operation theatre items, consumables, optical frames and lens are valued at lower of cost and net realizable value. Cost is arrived at on first in first out basis except for opticals and lens. Stores & spares which do not meet the definition of Property, Plant and Equipment are accounted as inventories. Net realizable value is the estimated selling price in the ordinary course of business, less estimated cost of completion and estimated costs necessary to make the inventory saleable.

1.8 Leases

With effect from 1st April 2019, Ind AS 116 – “Leases” supersedes Ind AS 17 – “Leases”. The Company has adopted Ind AS 116 using the prospective approach. The application of Ind AS 116 has resulted into recognition of ‘Right-of-Use’ asset with a corresponding lease liability in the balance sheet.

The company as lessor

Lease income on an operating lease is recognized in the statement of profit and loss on a straight line basis over the term of the relevant lease except to the extent that the lease payments are structured to compensate for the expected inflationary cost.

The company as lessee

The company as a lessee, recognizes a right-of-use asset and a lease liability for its leasing arrangements, if the contract conveys the right to control the use of an identified asset.

The contract conveys the right to control the use of an identified asset, if it involves the use of an identified asset and the Company has substantially all of the economic benefits from use of the asset and has right to direct the use of the identified asset. The cost of the right-of-use asset shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date plus any initial direct costs incurred. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the written down value method from the commencement date over the shorter of lease term or useful life of right-of-use asset

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the lease.

Lease liability and ROU asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

1.9 Financial Instruments

Financial Assets and financial liabilities are recognized when a Company entity becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in Profit and Loss.

De-recognition of financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and the transfer qualifies for de-recognition under Ind AS – 109. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognizes its retained interest in the asset and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received.

On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income and accumulated in equity is recognized in profit or loss if such gain or loss would have otherwise been recognized in profit or loss on disposal of that financial asset.

De-recognition of Financial Liabilities

The Company derecognizes financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. An exchange between with a lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, a substantial modification of the terms of an existing financial liability is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in the Statement of Profit and Loss.

Cash and Cash Equivalents:

The Company considers all highly liquid financial instruments which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and Cash Equivalents consist of cash on hand, balances with banks which are unrestricted for withdrawal and usage.

1.10 Revenue recognition

(i) Rendering of Eye care Services

Revenue from eye care services includes consultancy, physical examinations, lab examinations, surgeries, nursing care, dietary and other allied services. The revenue for these services are recognised based on the transaction value (net off discounts and waivers) when each separate performance obligation is satisfied to the extent it is probable that the economic benefit will flow to the entity. The revenue realisable from insurance claims are recognised at the earlier of settlement or acceptance of claim by the insurance company.

(ii) Sale of goods

Revenue from sale of goods include optical sales, pharmacy sales and canteen sales. The revenue for these goods are recognised where the performance obligation is satisfied and the control of these goods are transferred to the customer. The revenue is stated exclusive of GST and are net of sales returns, discounts, provision for anticipated returns on expiry, made on the basis of management expectation taking into account past experience.

(iii) Interest income

For all financial instruments measured at amortized cost, interest income is recorded using the effective interest rate, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial instrument. Interest income is included in 'Other Income' in the Statement of Profit and Loss.

1.11 Employee Benefits

Payments to defined contribution retirement benefit plans are recognized as an expense when employees have rendered service entitling them to the contributions.

Liabilities with regard to the Gratuity plan are determined by actuarial valuation, performed by an independent actuary, at each Balance sheet date using the projected unit credit method. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding interest), is reflected immediately in the statement of financial position with a charge or credit recognized in other comprehensive income in the period in which they occur. Re-measurement recognized in other comprehensive income is reflected immediately in retained earnings and will not be reclassified to profit or loss. Past service cost is recognized in profit or loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset.

1.12 Provisions

A provision is recognised when the Company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources embedded and that the company will be required to settle the obligation, in respect of which a reliable estimate can be made of the amount of obligation.

1.13 Taxes on Income

i. Current Tax:

Tax on Income for the current period is determined on the basis of taxable income and tax credit computed in accordance with the provisions of the Income Tax Act 1961, and based on the expected outcome of assessments/ appeals.

ii. Deferred Tax:

Deferred Tax is recognized on timing difference between accounting income and the taxable income for the year quantified using the tax rates and laws enacted or substantively enacted as on the balance sheet date. Deferred Tax assets are recognized and carried forward to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

Minimum Alternate Tax ("MAT") credit is recognized as an asset only when and to the extent there is convincing evidence that the company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset in accordance with the recommendations contained in the Guidance note issued by Institute of Chartered Accountants of India ("ICAI"), the said asset is created by way of credit to Statement of Profit and Loss. The company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT credit entitlement to the extent there is no longer convincing evidence to the effect that company will pay normal income tax during the specified period.

1.14 Earnings Per Share

Basic Earnings Per Share are computed by dividing profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the year. The Company did not have any potentially dilutive securities in any of the years presented.

1.15 Contingent Liabilities

Disclosure of contingent liability is made when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources embodying economic benefits will be required to settle or a reliable estimate of amount cannot be made.

Contingent liabilities, which are considered significant and material by the Company, but not provided for in the books of accounts, are disclosed by way of notes to accounts.

The Company has ongoing disputes with tax authorities and forum mainly relating to treatment of characterization and classification of certain items. The Company has demands amounting to Rs. 82.17 Lakhs and Rs. 84.20 Lakhs as at March 31, 2025 and 2024, respectively from various tax authorities and forum which are being contested by the Company based on the management evaluation and on the advice of tax consultants.

1.16 Segment reporting

The company is engaged in the business of healthcare activities. Hence, there is only one reportable segment.

1.17 Statement of Cash flows

Cash flows are reported using the indirect method, whereby profit / (loss) before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are based on classification made in a manner considered most appropriate to Company's business.

Lotus Eye Hospital and Institute Limited
Notes to the financial statements for the year ended March 31, 2025
(All amounts are in Rupees Lakhs unless otherwise stated)

Note 2: Property, Plant and Equipment (PPE)

The changes in the carrying value of property, plant and equipment for the year ended March 31, 2025 and March 31, 2024 were as follows:

Particulars	Land	Building	Improvements to leasehold building	Furniture & Fixtures	Office Equipments	Electrical Equipments	Plant & Machinery	Hospital Equipments	Computer	Vehicles	Total
Gross carrying amount											
As at 1st April, 2023	2,583.83	1,247.49	270.11	252.65	358.05	98.03	100.82	3,579.90	176.21	142.59	8,809.68
Additions for the year	-	-	206.03	36.99	45.48	20.82	4.09	223.15	13.33	6.69	556.58
Disposals/ Adjustments for the year	-	-	-	-	-	2.92	-	76.48	-	-	79.40
As at 1st April, 2024	2,583.83	1,247.49	476.14	289.64	403.53	115.93	104.91	3,726.57	189.54	149.28	9,286.86
Additions for the year	-	-	192.06	18.80	48.55	23.93	8.13	168.99	15.55	7.07	483.08
Disposals/ Adjustments for the year	-	-	-	-	1.90	1.45	-	11.04	29.78	7.73	51.90
As at 31st March, 2025	2,583.83	1,247.49	668.20	308.44	450.18	138.41	113.04	3,884.52	175.31	148.62	9,718.04
Accumulated depreciation											
As at 1st April, 2023	-	627.71	31.26	172.05	275.72	80.72	87.28	2,924.18	132.06	131.69	4,462.67
Depreciation for the year	-	29.84	41.66	26.52	28.43	6.83	3.21	149.44	21.00	2.56	309.49
Depreciation withdrawn during the year	-	-	-	-	-	1.80	-	70.85	-	-	72.65
As at 1st April, 2024	-	657.55	72.92	198.57	304.15	85.75	90.49	3,002.77	153.06	134.25	4,699.51
Depreciation for the year	-	11.56	66.84	11.39	15.58	4.69	2.05	67.99	10.94	2.44	193.48
Depreciation withdrawn during the year	-	-	-	-	1.80	1.21	-	10.49	28.29	7.34	49.13
As at 31st March, 2025	-	669.11	139.76	209.96	317.93	89.23	92.54	3,060.27	135.71	129.35	4,843.86
Net Carrying Value											
As at March 31, 2024	2,583.83	589.94	403.22	91.07	99.38	30.18	14.42	723.80	36.48	15.03	4,587.35
As at March 31, 2025	2,583.83	576.38	528.44	98.48	132.25	49.18	20.50	824.25	39.60	19.27	4,874.18

Notes :

- All the Title deeds of Land & Building (other than leasehold buildings) are held in the name of the company.
- The company has not revalued any of its assets during the year.
- The company has not created any charge on its property, plant and equipment.
- The aggregate depreciation has been included under depreciation and amortization expense in the Statement of Profit and Loss.
- During the period ended 31st March, 2025, the Company has changed its method of depreciation from its existing method of written down value to straight line method taking into account its reassessment of the expected pattern of economic benefits from those assets. Had the Company continued its previous method of written down value for these assets, depreciation expense for the year ended 31st March 2025 would have been higher by Rs.

Lotus Eye Hospital and Institute Limited

Notes to the financial statements for the year ended March 31, 2025

(All amounts are in Rupees Lakhs unless otherwise stated)

Note 3: Right of use assets (ROU)

Particulars	Hospital equipments	Land & Building	Total
Gross carrying amount			
As at 1st April, 2023	-	137.82	137.82
Additions for the year	270.46	-	270.46
Disposals/ Adjustments for the year	-	-	-
As at 1st April, 2024	270.46	137.82	408.28
Additions for the year	134.86	220.21	355.07
Disposals/ Adjustments for the year	-	137.82	137.82
As at 31st March, 2025	405.32	220.22	625.53
Accumulated depreciation			
As at 1st April, 2023	-	77.37	77.37
Depreciation for the year	16.32	44.27	60.59
Depreciation withdrawn during the year	-	-	-
As at 1st April, 2024	16.32	121.64	137.96
Depreciation for the year	23.32	82.03	105.35
Depreciation withdrawn during the year	-	137.82	137.82
As at 31st March, 2025	39.64	65.86	105.50
Net Carrying Value			
As at March 31, 2024	254.14	16.18	270.32
As at March 31, 2025	365.68	154.36	520.04

Note 4: Capital work in progress

The changes in capital work-in-progress for the year ended March 31, 2025 and March 31, 2024 are as follows:

Particulars	Others	Total
As at 1st April, 2023	-	-
As at 1st April, 2024	7.73	7.73
As at 31st March, 2025	-	-

Capital Work-in-progress (CWIP) for ageing schedule - 2024-25

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

Capital Work-in-progress (CWIP) for ageing schedule - 2023-24

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	7.73	-	-	-	7.73
Projects temporarily suspended	-	-	-	-	-

Note 5: Intangible assets

The changes in the carrying value of acquired intangible assets for the year ended March 31, 2025 and March 31, 2024 are as follows:

Particulars	Computer software	Total
Gross carrying amount		
As at 1st April, 2023	70.40	70.40
Additions for the year	-	-
Disposals/ Adjustments for the year	-	-
As at 1st April, 2024	70.40	70.40
Additions for the year	7.38	7.38
Disposals/ Adjustments for the year	-	-
As at 31st March, 2025	77.78	77.78
Accumulated amortisation		
As at 1st April, 2023	60.25	60.25
Amortisation for the year	2.71	2.71
Amortisation withdrawn during the year	-	-
As at 1st April, 2024	62.96	62.96
Amortisation for the year	1.86	1.86
Amortisation withdrawn during the year	-	-
As at 31st March, 2025	64.82	64.82
Net Carrying Value		
As at March 31, 2024	7.44	7.44
As at March 31, 2025	12.96	12.96

Notes :

- The company does not have any intangible asset under development as on 31.03.2025
- The amortization expense has been included under depreciation and amortization expense in the Statement of Profit and Loss.

**Lotus Eye Hospital and Institute
Limited**

**Notes to the financial statements for the year ended March 31,
2025**

*(All amounts are in Rupees Lakhs unless otherwise
stated)*

Note 6: Other Financial Assets

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
	Unsecured, Considered Good		
(a)	Rental and Lease Deposits	146.89	143.39
(b)	Security Deposits	28.32	28.20
(c)	Deposits Paid under Protest	63.57	63.57
		238.78	235.16

Note 7: Deferred Tax Assets (Net)

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
The major components of deferred tax assets arising on account of timing differences are as follows:			
	Deferred tax asset		
	- Property, plant and equipment	(31.20)	24.02
	- Expenses allowable against taxable income in future years	3.52	2.66
	- Retirement benefit plan	9.48	3.77
	- Minimum alternate tax (MAT) credit	23.51	-
	- Business Loss	2.86	
		8.16	30.45

Movement of Deferred Tax Assets;

Sr. No	Particulars	Opening balance	Set off during the year	Recognised in the statement of profit and loss	Recognised in other comprehensive income	Closing balance
(a)	Property, plant and equipment	24.02	-	(55.22)	-	(31.20)
(b)	Retirement benefit plan	3.77	-	-	5.71	9.48
(c)	Expenses allowable against taxable income in future years	2.66	-	0.86	-	3.52
(d)	Minimum alternate tax (MAT) credit	-	-	23.51	-	23.51
(e)	Business Loss	-	-	2.86	-	2.86
		30.45	-	(27.99)	5.71	8.16

Note 8: Other Non-Current Assets

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
	<i>Unsecured, Considered good</i>		
(a)	Capital advances	60.53	60.53
(b)	Balances from statutory authorities	85.71	59.51
(c)	Surplus Contribution to Gratuity fund [^]	-	2.47
		146.24	122.51

[^] The present value of obligations has been set off against the fair value of plan assets to arrive at the net liability arising from defined benefit obligations as per Ind AS 19.

Note 9: Inventories

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
	(valued at lower of cost and net realizable value)		
(a)	Consumables	203.50	160.45
(b)	Pharmacy	58.19	42.72
(c)	Optical frames & lens	103.74	101.57
(d)	Contact lens	4.30	3.64
(e)	Stores & Spares	12.46	12.07
(f)	Canteen stock	0.77	0.71
		382.96	321.16

Note 10: Trade Receivables

Particulars	As at March 31, 2025	As at March 31, 2024
Unsecured - considered good		
-Receivable from Insurance Companies	142.55	131.89
-Receivable from Others	9.73	9.27
Less : Expected credit loss#	(19.98)	(15.38)
	132.30	125.78

#Movements in expected credit loss

Opening	15.38	20.52
Add : Provision created for current year	6.00	2.20
Less : Utilized during current year	(1.40)	(7.34)
Closing	19.98	15.38

The company has written off trade receivables of Rs. 1.40 Lakhs during the year and has utilized the existing allowances towards expected credit loss as the company does not expect future cash flows/recoveries from these receivables.

Trade Receivables ageing schedule for the year ended March 31,2025

Particulars	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Undisputed Trade receivables– considered good	55.91	42.06	27.20	21.39	5.73	152.28
Undisputed Trade Receivables– which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivables– credit impaired	-	-	-	-	-	-
Disputed Trade Receivables– considered good	-	-	-	-	-	-
Disputed Trade Receivables–which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivables– credit impaired	-	-	-	-	-	-
	<u>55.91</u>	<u>42.06</u>	<u>27.20</u>	<u>21.39</u>	<u>5.73</u>	<u>152.28</u>
Less: Expected Credit Loss						<u>19.98</u>
Total						<u><u>132.30</u></u>

Trade Receivables ageing schedule for the year ended March 31,2024

Particulars	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Undisputed Trade receivables– considered good	80.25	23.01	29.34	4.64	3.92	141.16
Undisputed Trade Receivables– which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivables– credit impaired	-	-	-	-	-	-
Disputed Trade Receivables– considered good	-	-	-	-	-	-
Disputed Trade Receivables–which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivables– credit impaired	-	-	-	-	-	-
	<u>80.25</u>	<u>23.01</u>	<u>29.34</u>	<u>4.64</u>	<u>3.92</u>	<u>141.16</u>
Less: Expected Credit Loss						<u>15.38</u>
Total						<u><u>125.78</u></u>

Note 11: Cash and Cash Equivalents

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	Cash in hand	11.36	7.04
(b)	Balance with banks		
(i)	In current accounts	38.79	(63.05)
(ii)	In deposit accounts ^	150.96	321.27
		201.11	265.26

^ Bank deposits with original maturity of less than 3 months.

Note 12: Bank balances other than above

Particulars	As at March 31, 2025	As at March 31, 2024
Balance with banks		
(i) In term deposit accounts ^	196.68	427.69
(ii) Earmarked balances		
In unpaid dividend *	10.01	11.09
In unspent CSR Account	7.28	-
	213.97	438.78

^ Bank deposits with original maturity of more than 3 months but less than 12 months.

* Unpaid dividend has been earmarked with a separate bank account. The unpaid dividend liability is disclosed under 'Other Financial Liabilities(current)'. Refer Note 21.

Note 13: Other Current Assets

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
	Unsecured, considered good		
(a)	Advance to suppliers	136.28	177.09
(b)	Advance to employees	17.61	5.60
(c)	Prepaid expenses	55.78	51.04
(d)	Other advances	17.00	17.00
		226.67	250.73

Lotus Eye Hospital and Institute Limited
Notes to the financial statements for the year ended March
31, 2025

(All amounts are in Rupees Lakhs unless otherwise stated)

Note 14: Share Capital

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
a)	Authorised 2,50,00,000 equity shares of Rs. 10 each	2,500.00	2,500.00
b)	Issued , subscribed and paid up 2,07,96,330 equity shares of Rs 10 each	2,079.63	2,079.63

(a) **Terms/ rights attached to equity shares**

The Company has only one class of shares referred to as equity shares having par value of Rs.10/-. Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

(b) **Details of shareholders holding more than 5% shares in the company**

Name of the shareholder	As at March 31, 2025		As at March 31, 2024	
	Number of shares	% of holding	Number of shares	% of holding
Ms Sangeetha Sundaramoorthy	39,39,909	18.95%	39,18,039	18.84%
Dr Kavetha Sundaramoorthy	39,05,356	18.78%	39,05,356	18.78%
Kovai Purani Finance Private Limited	13,86,805	6.67%	13,16,699	6.33%

(c) **Reconciliation of equity shares outstanding at the beginning and at the end of the period**

Particulars	As at March 31, 2025		As at March 31, 2024	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the period	2,07,96,330	2,079.63	2,07,96,330	2,079.63
Add : Shares issued during the year	-	-	-	-
Less : Shares bought back during the year	-	-	-	-
Outstanding at the end of the period	2,07,96,330	2,079.63	2,07,96,330	2,079.63

(d)

Disclosure of Shareholding of Promoters

Name of the Promoter	No. of shares as on March 31, 2025	% of Total Shares as on March 31, 2025	No. of shares as on March 31, 2024	% of Total Shares as on March 31, 2024	% Increase / (decrease) during the year
Ms Sangeetha Sundaramoorthy	39,39,909	18.95%	39,18,039	18.84%	0.11%
Dr Kavetha Sundaramoorthy	39,05,356	18.78%	39,05,356	18.78%	0.00%
Dr S Rajkumar	17,200	0.08%	2,83,485	1.36%	-1.28%
Dr S K Sundaramoorthy	5,01,837	2.41%	5,01,837	2.41%	0.00%
S.A. Karuppasamy	-	0.00%	100	0.00%	0.00%
V. Saroja	-	0.00%	100	0.00%	0.00%
Total	83,64,302	40.22%	86,08,917	41.40%	

Note : 5,01,837 equity shares of Promoter Late Dr S K Sundaramoorthy are lying in his account without a nominee.
 The company has not bought back any of its shares and has no stock option plans.

(e)

Note 15: Other Equity

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
a)	Securities premium reserve	2,514.14	2,514.14
b)	Retained earnings	1,430.85	1,356.92
c)	Other comprehensive income	(24.59)	(9.77)
		3,920.40	3,861.29

Notes

- a. Securities premium is used to record premium received on issue of shares. The reserve is utilised in accordance with the provisions of the Companies Act, 2013.
- b. Retained earnings represent the surplus / accumulated earnings of the company and are available for distribution to share holders.

Note 16: Lease Liabilities

Particulars	As at March 31, 2025	As at March 31, 2024
<i>Unsecured</i>		
Long term maturities of finance lease obligations ^	120.17	68.86
Long term maturities of operating lease obligations ^	82.50	-
	202.67	68.86

^ Current maturities of lease obligations has been disclosed under 'Lease liabilities' Note 19 & Refer Note 36

Note 17: Trade Payables (Non-current)

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	Total outstanding dues of creditors other than micro and small enterprises	-	7.68
		-	7.68

Trade Payables (Non-current) Ageing Schedule for the year ended March 31,2025

Sr. No	Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
a)	MSME	-	-	-	-	-
b)	Others	-	-	-	-	-
c)	Disputed dues - MSME	-	-	-	-	-
d)	Disputed dues - Others	-	-	-	-	-
e)	Total	-	-	-	-	-

Trade Payables (Non-current) Ageing Schedule for the year ended March 31,2024

Sr. No	Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
a)	MSME	-	-	-	-	-
b)	Others	7.68	-	-	-	7.68
c)	Disputed dues - MSME	-	-	-	-	-
d)	Disputed dues - Others	-	-	-	-	-
e)	Total	7.68	-	-	-	7.68

Note 18: Other Financial Liabilities

Particulars	As at March 31, 2025	As at March 31, 2024
(a) Caution deposits received from		
(i) Doctors	1.30	2.10
(ii) Employees	10.71	9.14
(iii) Others	0.20	0.20
	12.21	11.44

Note 19: Lease Liabilities

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
	<i>Unsecured</i>		
(a)	Current maturities of finance lease obligations ^	60.55	22.97
(b)	Current maturities of operating lease obligations ^	79.80	19.21
		140.35	42.18

^ Long term maturities of lease obligations has been disclosed under ' Lease liabilities' Note 16 & Refer Note 36

Note 20: Trade Payables

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	Total outstanding dues of micro enterprises and small enterprises	54.71	21.28
(b)	Total outstanding dues of creditors other than micro and small enterprises	281.58	324.40
	Total	336.29	345.68

Disclosure relating to Micro, Small and Medium Enterprises (MSMEs)

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	The principal amount and the interest due thereon remaining unpaid to MSME suppliers.	54.71	21.28
(b)	The amount of interest paid by the buyer in terms of section 16 of the Act, along with the amount of the payment made to the supplier beyond the appointed day during the year.	-	-
(c)	The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	-	-
(d)	The amount of interest accrued and remaining unpaid	-	-
(e)	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Act.	-	-

Note : As defined under Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006) (the "Act"), the disclosure in respect of the amounts payable to such enterprises as at the end of the year has been made in the financial statements based on the information received and available with the Company.

Trade Payables Ageing Schedule for the year ended March 31,2025

Sr. No	Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
a)	MSME	54.10	0.61			54.71
b)	Others	241.53	17.60	12.77	9.68	281.58
c)	Disputed dues - MSME	-	-	-	-	-
d)	Disputed dues - Others	-	-	-	-	-
e)	Total	295.63	18.21	12.77	9.68	336.29

Trade Payables Ageing Schedule for the year ended March 31, 2024

Sr. No	Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
(a)	MSME	20.84	-	0.43	-	21.27
(b)	Others	299.69	17.53	5.10	2.09	324.41
(c)	Disputed dues – MSME	-	-	-	-	-
(d)	Disputed dues - Others	-	-	-	-	-
	Total	320.53	17.53	5.53	2.09	345.68

Note 21: Other Financial Liabilities

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	Salaries and reimbursements to employees	81.17	73.84
(b)	Professional and doctor's fees payable	67.52	52.35
(c)	Liability for unspent CSR Obligation	7.28	7.28
(d)	Other Payables	16.47	19.32
(e)	Unpaid dividends	10.01	11.09
		182.45	163.88

Note 22: Other Current Liabilities

Sr. No	Particulars	As at March 31, 2025	As at March 31, 2024
(a)	Advances from customers	26.90	42.22
(b)	Statutory dues	44.82	39.81
		71.72	82.03

Note 23: Provisions

Particulars	As at March 31, 2025	As at March 31, 2024
<i>Provision for employee benefits</i>		
Gratuity^	11.65	-
	11.65	-

^ The present value of obligations has been set off against the fair value of plan assets to arrive at the net liability arising from defined benefit obligations as per Ind AS 19.

Lotus Eye Hospital and Institute Limited**Notes to the financial statements for the year ended March 31, 2025***(All amounts are in Rupees Lakhs unless otherwise stated)***Note 24: Revenue from operations**

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	<i>Sale of services</i>		
	Revenue from medical services	3,514.00	3,409.53
(b)	<i>Sale of goods</i>		
	Revenue from sale of opticals & contact lens	864.02	866.34
	Revenue from pharmacy	482.26	448.19
(c)	<i>Other operating revenue</i>	95.97	96.93
		4,956.25	4,820.99

Note 25: Other income

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	<i>Interest income</i>		
	from bank deposits	35.08	49.75
	from others	0.73	-
(b)	Rent receipts	43.95	43.95
(c)	Other income	50.37	36.57
		130.13	130.27

Note 26: Cost of materials consumed

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Opening stock	160.45	141.89
Add: Purchases	866.68	862.79
Less: Closing stock	(203.50)	(160.45)
	823.63	844.23

Note 27: Purchases of stock-in-trade

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Opticals and lens	347.90	338.22
(b)	Pharmacy	332.48	310.25
(c)	Canteen and utility purchases	60.06	56.58
		740.44	705.05

Note 28: Changes in inventories of stock in trade

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Opening stock	148.64	131.46
Closing stock	(167.00)	(148.64)
(increase) / decrease in inventories	(18.36)	(17.18)

Note 29: Service expenses

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Retainer fees to doctors	815.46	641.38
(b)	Power and fuel	129.14	119.76
		944.60	761.14

Note 30: Employee benefits expense

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Salaries and wages	966.71	804.36
(b)	Bonus and incentives	21.73	20.33
(c)	Director remuneration	54.00	42.87
(d)	Contribution to provident and other funds	77.74	69.32
(e)	Provision for gratuity	10.85	11.17
(f)	Staff welfare expenses	22.08	19.71
(g)	Directors sitting fees	8.10	13.25
		1,161.21	981.01

Note 31: Finance costs

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Interest on finance lease	17.69	5.05
(b)	Interest on operating lease	17.81	4.69
		35.50	9.74

Note 32: Depreciation and amortization expense

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Depreciation on Property, Plant and Equipment (Refer Note.2)	193.48	309.49
(b)	Depreciation on right of use assets (Refer Note.3)	105.35	60.59
(c)	Amortisation on intangible assets (Refer Note.5)	1.86	2.71
		300.68	372.78

Note 33: Other expenses

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Rent	236.74	217.95
(b)	Advertisement, publicity and marketing	94.63	127.80
(c)	<i>Repairs</i>		
	Repairs to equipment and machinery	194.52	151.78
	Repairs to building	15.77	6.03
	Repairs to vehicles	25.61	26.11
	Repairs to others	5.84	6.22
(d)	House keeping expenses	104.66	88.45
(e)	Legal and professional fees	22.86	25.83
(f)	Security charges	40.02	36.48
(g)	Printing and stationery	24.00	18.16
(h)	Telephone expenses	18.48	16.75
(i)	Water charges	22.23	18.71
(j)	Rates and taxes, excluding taxes on income	11.11	13.89
(k)	Insurance	12.65	11.56
(l)	Bad debts	0.10	-
(m)	Provision for doubtful debts	6.00	2.20
(n)	Membership and subscriptions	7.17	9.40
(o)	Bank charges	12.55	10.35
(p)	<i>Payment to auditors</i>		
	for Statutory audit	4.00	4.00
	for Internal audit	5.00	5.00
	for Tax audit	1.02	0.80
	for Other taxation matters	0.20	0.43
(q)	Travelling and conveyance	19.91	14.15
(r)	Laboratory expenses	5.84	5.36
(s)	Postage and telegram	5.82	5.06
(t)	Licences	7.99	13.37
(u)	Recommendation charges	41.89	35.83
(v)	Office Maintenance and others	6.80	3.87
(w)	Meeting expenses	7.23	7.88
(x)	Contribution towards Corporate Social Responsibility	-	7.78
(y)	Discount allowed	0.76	1.01
(z)	Provision for compensation expenses	-	1.50
		961.40	893.71

Note 34: Exceptional items

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Net loss/(gain) on sale of items of property, plant and equipment	(0.98)	(0.59)
		(0.98)	(0.59)

Note 35: Tax expenses

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	<i>Current Tax</i>		
	In respect of the current year	23.50	101.39
	In respect of the earlier years	12.84	(1.20)
		36.34	100.19
(b)	<i>Deferred tax</i>		
	In respect of the current year	27.99	9.73
	In respect of the earlier years	-	-
		27.99	9.73
	Total tax expense	64.33	109.92

The reconciliation of estimated income tax expense at tax rate to income tax expense reported in Statement of Profit and Loss :

S.no.	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(a)	Profit before tax expenses	138.26	401.37
	Enacted tax rate	27.82%	27.82%
	Expected income tax expense at statutory tax rate	38.46	111.66
(b)	Tax effects of amounts which are not deductible/(taxable) in calculating taxable income :		
	(1) Expenses not deductible for determining taxable profit	5.86	3.82
	(2) Expenses deductible for determining taxable profit	7.17	(4.36)
	(3) Prior year taxes	12.84	(1.20)
	Reconciliation difference	25.87	(1.74)
(c)	Income tax expenses	64.33	109.92
	Effective income tax rate	46.53%	27.39%

Note : The above computation is based on provisional statement of taxes and the figures are subject to tax audit and filing of tax returns in the due course.

Lotus Eye Hospital and Institute Limited**Notes to the financial statements for the year ended March 31, 2025***(All amounts are in Rupees Lakhs unless otherwise stated)***Note 36 : Leases****(A) Finance leases**

The company had adopted Ind AS 116 'Leases' on all lease contracts with effect from April 01, 2019

The company has taken certain medical equipments under finance lease. The leases typically run for a term ranging from 3-5 years. The company has option to purchase the equipment for a nominal amount at the end of the lease term. The company's obligations under finance leases are secured by the lessors' title to the leased assets.

The disclosures as required under the standard are given below:

Right of use (ROU) Asset	As at March 31, 2025	As at March 31, 2024
Gross value	405.32	270.46
Less: Accumulated Depreciation	(39.64)	(16.32)
Carrying amount	365.68	254.14
Lease liability	As at March 31, 2025	As at March 31, 2024
Gross value	226.69	102.46
Less: Reduction in lease liability	(45.97)	(10.63)
Carrying amount	180.72	91.83
Current portion of lease liability	60.54	22.97
Non-current portion of lease liability	120.18	68.86
Amount recognised as lease interest during the year	17.69	5.05

Details of maturities of finance lease liabilities:

Particulars	Future minimum lease payments	
	As at March 31, 2025	As at March 31, 2024
(i) not later than one year	76.36	31.36
(ii) later than one year and not later than five years	132.28	78.40
(iii) later than five years	-	-
	208.64	109.76
Less: future finance costs		
(i) not later than one year	15.81	8.39
(ii) later than one year and not later than five years	12.11	9.54
(iii) later than five years	-	-
Closing balance	180.72	91.83

(B) Operating leases

Right of use (ROU) Asset	As at March 31, 2025	As at March 31, 2024
Gross value	262.54	137.82
Less: Accumulated Depreciation	(108.18)	(121.64)
Carrying amount	154.36	16.18

Lease liability	As at March 31, 2025	As at March 31, 2024
Gross value	239.42	67.05
Less: Reduction in lease liability	(77.12)	(47.84)
Carrying amount	162.30	19.21
Current portion of lease liability	79.81	19.21
Non-current portion of lease liability	82.49	-
Amount recognised as lease interest during the year	17.81	4.69

Details of maturities of operating lease liabilities:

Particulars	Future minimum lease payments	
	As at March 31, 2025	As at March 31, 2024
(i) not later than one year	92.83	20.02
(ii) later than one year and not later than five years	87.41	-
(iii) later than five years	-	-
	180.24	20.02
Less: future finance costs		
(i) not later than one year	13.03	0.81
(ii) later than one year and not later than five years	4.91	-
(iii) later than five years	-	-
Closing balance	162.30	19.21

Lotus Eye Hospital and Institute Limited

Notes to the financial statements for the year ended March 31, 2025

(All amounts are in Rupees Lakhs unless otherwise stated)

Note 37 : Disclosures on financial instruments

Financial assets and liabilities

The following table presents the carrying amounts and fair value of each category of financial assets and liabilities as at March 31, 2025.

Financial assets

Sr. No	Particulars	Cash, and other financial assets at amortised cost	Total carrying value	Total fair value
(a)	Trade receivables	132.30	132.30	132.30
(b)	Cash and cash equivalents	201.11	201.11	201.11
(c)	Bank balances other than above	213.97	213.97	213.97
(d)	Other financial assets - non-current	238.78	238.78	238.78
		786.16	786.16	786.16

Financial liabilities

Sr. No	Particulars	Other financial liabilities (at amortised cost)	Total carrying value	Total fair value
(a)	Lease liabilities- non current	202.67	202.67	202.67
(b)	Lease liabilities- current	140.35	140.35	140.35
(c)	Trade payables- non current	-	-	-
(d)	Trade payables- current	336.29	336.29	336.29
		679.31	679.31	679.31

The following table presents the carrying amounts and fair value of each category of financial assets and liabilities as at March 31, 2024.

Financial assets

Sr. No	Particulars	Cash, and other financial assets at amortised cost	Total carrying value	Total fair value
(a)	Trade receivables	125.78	125.78	125.78
(b)	Cash and cash equivalents	265.26	265.26	265.26
(c)	Bank balances other than above	438.78	438.78	438.78
(d)	Other financial assets - non-current	235.16	235.16	235.16
		1,064.98	1,064.98	1,064.98

Financial liabilities

Sr. No	Particulars	Other financial liabilities (at amortised cost)	Total carrying value	Total fair value
(a)	Lease liabilities- non current	68.86	68.86	68.86
(b)	Lease liabilities- current	42.18	42.18	42.18
(c)	Trade payables- non current	7.68	7.68	7.68
(d)	Trade payables- current	345.68	345.68	345.68
		464.40	464.40	464.40

Note 37 : Disclosures on financial instruments (Continued)**Credit risk**

Credit risk is the risk of financial loss arising from counterparty failure to repay or service debt according to the contractual terms or obligations. Credit risk encompasses both the direct risk of default and the risk of deterioration of creditworthiness as well as concentration risks.

Financial instruments that are subject to concentrations of credit risk, principally consist of investments classified as fair value through profit and loss, trade receivables, loans and advances and derivative financial instruments. The Company strives to promptly identify and reduce concerns about collection due to a deterioration in the financial conditions and others of its main counterparties by regularly monitoring their situation based on their financial condition. None of the financial instruments of the Company result in material concentrations of credit risks.

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is Rs. 786.16 Lakhs as at March 31, 2025 and Rs. 1064.98 Lakhs as at March 31, 2024, respectively, being the total of trade receivables, cash & cash equivalents, other bank balances and non-current financial assets.

Financial assets that are neither past due nor impaired

None of the Company's cash equivalents or other bank balances are past due or impaired. Regarding trade receivables that are neither impaired nor past due, there were no indications as at March 31, 2025 and March 31, 2024, that defaults in payment obligations will occur.

Credit quality of financial assets and impairment loss

The quality of financial assets can be assessed by way of ageing analysis of trade receivables discussed in "Note : 7 Trade Receivables".

Liquidity risk

Liquidity risk refers to the risk that the Company will encounter difficulty to meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements.

Financial liabilities

Particulars	Due in 1st year	Due in 2nd to 5th year	Due after 5th year	Total
Trade payables	336.29	-	-	336.29
Lease liabilities	140.36	202.67	-	343.03
	476.65	202.67	-	679.32

Foreign currency exchange rate risk:

Since the company did not have any cash inflows or outflows in foreign currency during the financial year, there is no foreign currency exchange rate risk.

Lotus Eye Hospital and Institute Limited

Notes to the financial statements for the year ended March 31, 2025

(All amounts are in Rupees Lakhs unless otherwise stated)

Note 38 : Related party disclosures

A. Name of the related parties and their relationship

Name	Relationship
Key Managerial personnel	
Dr Kavetha Sundaramoorthy	Chairman
Ms Sangeetha Sundaramoorthy	Managing director
Dr K S Ramalingam	Chief Executive Officer & Executive Director
Dr S Natesan	Non- Executive - Independent director
Mr Karthik Veeramani	Non- Executive - Independent director
CA Perumalsamy Mahendran	Non- Executive - Independent director
CA Reghunathan Ramanujam	Chief Financial Officer
CS Achuth Menon	Company Secretary
Dr D R Kaarthikeyan	Non executive director (Retired)
Dr Yogesh Shah	Non executive director (Retired)
CA M Alagiriswamy	Non executive director (Retired)

Enterprises owned or significantly influenced by key management personnel ('KMP') or their relatives - (with whom transactions have been taken place)

M/s. Lotus Vision Research Trust

M/s. Coimbatore Kidney Care And Research Limited

B. Related party transactions

	Name	Nature of transaction	Transaction		Outstanding Balances	
			For the year ended	For the year ended	As at March 31, 2025	As at March 31, 2024
			March 31, 2025	March 31, 2024		
Ms Sangeetha Sundaramoorthy		Dividend Paid	-	19.59	-	-
		Remuneration	42.00	30.87	(2.58)	-
		Rent paid	1.57	-	(0.85)	-
Dr Kavetha Sundaramoorthy		Dividend Paid	-	19.53	-	-
		Director sitting fee	0.90	1.50	-	-
Dr S Rajkumar		Dividend Paid	-	15.74	-	-
Dr S K Sundaramoorthy		Dividend Paid	-	2.51	-	-
S.A. Karuppasamy		Dividend Paid	-	0.00	-	-
V. Saroja		Dividend Paid	-	0.00	-	-
Dr K S Ramalingam		Dividend Paid	-	1.49	-	-
		Remuneration	12.00	12.00	(1.00)	(0.81)
Dr D R Kaarthikeyan		Director sitting fee	1.00	2.00	-	-
Dr Yogesh Shah		Director sitting fee	1.00	2.00	-	-
CA Perumalsamy Mahendran		Director sitting fee	1.40	1.75	-	-
CA M Alagiriswamy		Director sitting fee	1.00	2.00	-	-
Dr S Natesan		Director sitting fee	1.40	2.00	-	-
Mr Kathik Veeramani		Director sitting fee	1.40	2.00	-	-
CA Reghunathan Ramanujam		Remuneration	22.65	16.97	(1.45)	(1.40)
CS Achuth Menon		Remuneration	12.26	10.76	(1.00)	(0.80)
M/s. Lotus Vision Research Trust		Rent received	43.95	43.95	-	-
M/s. Lotus Vision Research Trust		Rent paid	65.21	63.13	-	-
M/s. Lotus Vision Research Trust		Rent paid- Equipment	7.42	-	-	-
M/s. Lotus Vision Research Trust		Electricity Charges	19.52	16.81	-	-
M/s. Lotus Vision Research Trust		Sale of equipment	-	-	-	-
M/s. Coimbatore Kidney Care And Research Limited		Medical services	0.61	0.82	(0.00)	-

Notes:

(i) Outstanding balances represents (payables) / receivables.

(ii) The related party has been identified as per Section 203 of Companies Act, 2013 and Ind AS 24 - Related Party Disclosures.

(iii) The remuneration to key management personnel does not include the provision made for Gratuity as they are determined on an actuarial basis for the company as a whole.

(iv) The transaction values are gross amounts exclusive of taxes.

Note 39 : Earnings per share (EPS)

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Net profit attributable to equity shareholders	73.93	291.45
b)	Weighted average number of equity shares for calculation of basic and diluted per share	2,079.63	2,079.63
c)	Profit per share basic and diluted [a/b*10] (in Rs.)	0.36	1.40

Note 40 : Employee Benefits

A. Defined contribution plan

The Company makes contributions towards provident fund and employees state insurance as a defined contribution retirement benefit fund for qualifying employees. The provident fund is operated by the regional provident fund commissioner. The Employees state insurance is operated by the Employees State Insurance Corporation. Under these schemes, the Company is required to contribute a specific percentage of the payroll cost as per the statute.

The total expenses recognized during the year in the statement of profit and loss was Rs. 77.74 lakhs (previous year : Rs. 69.32 lakhs), and it represents contributions payable to these plans by the Company.

B. Defined benefit plans

Gratuity

The Company operates post-employment defined benefit plan that provide gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement/exit. The Company's obligation in respect of the gratuity plan, which is a defined benefit plan, is provided for based on actuarial valuation carried out by an independent actuary using the projected unit credit method. The Company recognizes actuarial gains and losses immediately in the statement of profit and loss. The Company accrues gratuity as per the provisions of the Payment of Gratuity Act, 1972 as applicable as at the balance sheet date.

The company contributes all ascertained liabilities towards gratuity to the Fund. The plan assets have been invested 100% in insurer managed funds. The company provides for gratuity , a defined benefit retiring plan covering eligible employees. The Gratuity plan provides a lump sum payment to the vested employees at retirement, death, incapacitation or termination of employment based on the respective employees salary and tenure of the employment with the company.

Disclosures of Defined Benefit Plans based on actuarial valuation reports

The present value of the defined benefit obligation, and the related current service cost and past service cost, were measured using the projected unit credit method.

Investment risk The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds. Plan investment is a mix of investments in government securities, and other debt instruments.

Interest risk A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan's debt investments

Longevity risk The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

Salary risk The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

Change in defined benefit obligation

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
	Present value of defined benefit obligation as at the beginning of the year	110.78	99.48
a)	Current service cost	11.62	11.92
b)	Interest cost	7.13	6.55
c)	Remeasurement (gains)/losses on account of change in actuarial assumptions	17.55	6.62
d)	Benefits paid and Charges deducted	(15.64)	(13.79)
e)	Present value of defined benefit obligation as at the end of the year	131.44	110.78

Changes in fair value of plan assets

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
	Fair value of plan assets as at the beginning of the year	113.24	100.79
a)	Expected return on plan assets	7.90	7.29
b)	Contribution less Risk premium	13.00	18.55
c)	Contribution to meet direct benefit payments	4.27	-
d)	Benefits paid and charges deducted	(11.37)	(13.79)
e)	Direct benefit payments	(4.27)	-
f)	Actuarial Gain/(loss) on plan assets	(2.98)	0.40
g)	Fair value of plan assets as at the end of the year	119.79	113.24

Actual return on plan assets

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Expected return on plan assets	7.90	7.29
b)	Actuarial gain / (loss) on plan assets	(2.98)	0.40
c)	Estimated actual return on plan assets	4.92	7.70

Actuarial gains and losses recognized

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Actuarial gain / (loss) for year - obligation	(17.55)	(6.62)
b)	Actuarial gain / (loss) for year - plan assets	(2.98)	0.40
c)	Subtotal	(20.53)	(6.22)
d)	Actuarial (gain) / loss recognized	20.53	6.22
e)	Unrecognized actuarial gains / (losses) at the end of the period	-	-

Amount recognised in balance sheet

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Present value of the obligation	131.44	110.78
b)	Fair value of Plans	119.79	113.24
	Amount determined under Para 63 and IND AS 19		
c)		11.65	(2.47)
d)	Net Defined benefit liability recognised in the Balance Sheet	11.65	-
e)	Present value of future reduction in contribution under Para 65 of IND AS 19	-	2.47
f)	Net Defined Benefit Asset recognised under para 64 of Ind AS 19	-	2.47

Expenses recognised in statement of profit and loss

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Current service cost	11.62	11.92
b)	Past service cost and (gain)/loss from settlements	-	-
c)	Return on plan assets (excluding amounts included in net interest expense)	-	-
d)	Net interest expense	(0.77)	(0.75)
e)	Total expenses/ (income) recognised in profit or loss	10.85	11.17

Expenses recognised in other comprehensive income

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Remeasurement on the net defined benefit liability:		
b)	Remeasurement (gains)/losses on account of plan obligations	17.55	6.62
c)	Difference on return on plan assets vs received	2.98	(0.40)
d)	Total of remeasurement (gain) / loss recognised in other comprehensive income (OCI)	20.53	6.22

Movements in the balance sheet

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Present value of defined benefit obligation as at the beginning of the year	(2.47)	(1.31)
b)	Amount recognised in profit and loss	10.85	11.17
c)	Amount recognised in other comprehensive income	20.53	6.22
d)	Contribution paid	(17.27)	(18.55)
e)	Adjustments to the opening balance	-	-
f)	Net liability arising from defined benefit obligation as at the end of the year	11.65	(2.47)

Amount for the current period

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Present value of obligation	131.44	110.78
b)	Plan assets	119.79	113.24
c)	Surplus/(Deficit)	(11.65)	2.47
d)	Experience adjustments on plan liabilities - (loss)/gain	(11.99)	(7.35)
e)	Impact of change in assumptions on plan liabilities - (loss)/gain	(5.56)	0.72
f)	Experience adjustments on plan assets - (loss)/gain	(2.98)	0.40
Major categories of plan assets (as percentage of total plan assets)			

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Government of India securities	0.00%	0.00%
b)	State government securities	0.00%	0.00%
c)	High quality corporate bonds	0.00%	0.00%
d)	Equity shares of listed companies	0.00%	0.00%
e)	Property	0.00%	0.00%
f)	Special deposit scheme	0.00%	0.00%
g)	Funds managed by insurer	100.00%	100.00%
h)	Others	0.00%	0.00%
i)	Total	100.00%	100.00%

Significant actuarial assumptions

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Discount rate(s)	6.34%	6.93%
b)	Expected rate(s) of salary increase	6.00%	5.00%
c)	Attrition rate	43.11%	52.60%
d)	Expected rate of return on plan assets	6.34%	6.93%
e)	Retirement age	58 years	58 years
f)	Pre-retirement mortality	Indian Assured Lives Mortality (2012-14) Ultimate	

Category of assets

The fair value of the plan assets as at the end of the reporting period for each category, are as follows

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Insurer managed funds	119.79	113.24

Sensitivity Analysis

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
(i) Discount Rate + 50 BP Defined Benefit Obligation [PVO]	6.84% 130.29	7.43% 110.04
Current Service Cost	14.63	11.52
(ii) Discount Rate - 50 BP Defined Benefit Obligation [PVO]	5.84% 132.61	6.43% 111.54
Current Service Cost	14.97	11.72
(iii) Salary Escalation Rate + 50BP Defined Benefit Obligation [PVO]	6.50% 132.92	5.50% 111.80
Current Service Cost	15.01	11.74
(iv) Discount Rate - 50 BP Defined Benefit Obligation [PVO]	5.50% 129.98	4.50% 109.76
Current Service Cost (BP Denotes basis "points")	14.60	11.50

Note 41 : Corporate Social Responsibility (CSR) expenditure

Sr. No	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a)	Amount required to be spent by the company during the year	-	7.78
b)	Amount of expenditure incurred	-	0.50
c)	Shortfall at the end of the year	-	7.28
d)	Total of previous years shortfall	7.28	-
e)	Reason for shortfall	Pretains to ongoing projects	There has been delay in confirmation of suitable CSR Project
f)	Nature of CSR activities	Promotion of Health care for needy people	Promotion of Health care for needy people
g)	Details of related party transactions	-	-
h)	Where a provision is made with respect to liability incurred by entering into contractual obligation	7.28	7.28

Note 42 : Financial Ratios

S.no.	Ratio	Formula	Unit of Measure	FY 2024-25	FY 2023-24	% change YoY	Reason for Variance (>25 %)
1	Current Ratio	Current Ratio = Current Assets / Current Liabilities	Times	1.56	2.21	-29.54%	Due in increase in current portion of lease liabilities & decrease in deposits
2	Return on Equity	Return on Equity = Net Profit after taxes - Preference dividend / Shareholder's Equity	Percentage	1.23	4.91	-74.88%	Due to decrease in profitability
3	Inventory Turnover Ratio	Inventory Turnover Ratio = Net Sales / Average Inventory	Times	14.08	16.06	-12.36%	No significant variance
4	Trade Receivables Turnover Ratio	Trade Receivables Turnover Ratio = Net Credit Sales / Average Accounts Receivables	Times	6.21	6.37	-2.45%	No significant variance
5	Trade Payable Turnover Ratio	Trade Payable Turnover Ratio = Net Credit Purchases / Average Accounts Payables	Times	4.71	4.75	-0.70%	No significant variance
6	Net Capital Turnover Ratio	Net Capital Turnover Ratio = Net Sales / Working Capital	Times	11.96	6.19	93.19%	Due to increase in creditors and other liabilities
7	Net Profit Ratio	Net Profit Ratio = Net Profit / Net Sales	Percentage	1.49	6.05	-75.33%	Due to decrease in profitability
8	Return on Capital Employed	Return on Capital Employed = Earnings before interest and taxes / Capital Employed	Percentage	2.90	6.93	-58.11%	Due to decrease in profitability

(The ratios for the quarter have been annualised)

Notes :

- 1 Debt-Equity Ratio and Debt Service Coverage Ratio are not applicable to the company as the company is debt free.
- 2 Return on Investment Ratio is not applicable as the company does not have any investments.
- 3 The entire net profit belongs to the equity shareholders as the company has not issued any preference shares.

Note 43: Other Statutory Information

(i) Benami property:

The company does not have any Benami property where any proceedings have been initiated or pending under the Benami Transactions (Prohibition) Act, 1988 during the year.

(ii) Borrowings :

The company has no borrowings from Banks or Financial Institutions on the basis of security of current assets during the year. Hence, there is no requirement of submission of stock statements to Banks.

(iii) Wilful Defaulter :

The company has not been declared as a wilful defaulter by any Bank or Financial Institution during the year.

(iv) Relationship with Struck off Companies :

The company did not have any transaction with the companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956.

(v) Registration of Charges :

Since the company is debt free, no charges or satisfaction are yet to be registered with the Registrar of Companies.

(vi) Layers of Companies :

The company does not hold any subsidiaries. Hence, compliance with the number of layers prescribed under Section 2(87) of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable.

(vii) Scheme of arrangements :

No scheme of arrangements has been approved by the Competent Authority in terms of Section 230 to 237 of the Companies Act, 2013.

(viii) Utilisation of Borrowed funds and share premium :

(A) The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

(B) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ix) Undisclosed Income :

The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.)

(x) Crypto / Virtual Currency :

The company has not traded or invested in Crypto/Virtual Currency during the year.

Note 44: Contingent Liabilities

Particulars	As at March 31, 2025	As at March 31, 2024
Claims against the company, disputed by the company, not acknowledged as debt		
(i) Income tax	55.40	55.40
(ii) Kerala VAT	26.77	26.77
(iii) Medical related	-	2.03

Notes:

(i) An order has been received from the Income-tax department for FY 2009-10 and FY 2016-17 for an amount of Rs. 0.13 Lakhs and Rs. 55.27 Lakhs. The demand of Rs. 0.13 Lakhs has been disagreed by the company. The demand of Rs. 55.27 Lakhs was for depositing specified bank notes during the demonetisation period. The company has filed an appeal against the said demand before Commissioner of Income-tax (Appeals), Coimbatore. The liability has been considered contingent until the conclusion of the appeal.

(ii) An order has been received from Kerala Sales Tax Department for an amount of Rs. 26.77 Lakhs. The company has filed an appeal against the said demand before Kerala Value Added Tax Appellate Tribunal and High Court of Kerala for an amount of Rs. 5.16 Lakhs and Rs. 21.61 Lakhs respectively. The liability has been considered contingent until the conclusion of the appeal.

(iii) A customer has filed a complaint against the company under section 35 of the Consumer Protection Act, 2023 before the District Consumer Disputes Redressal Forum, Coimbatore for an amount of Rs.2.03 Lakhs. The liability has been considered contingent during the FY 2023-24. The court has dismissed the petition and ordered in our favour on 16-05-2024.

(iv) The Company believes that none of the above matters, either individually or in aggregate, are expected to have any material adverse effect on its financial statements. The cash flows in respect of above matters are determinable only on receipt of judgements/decisions pending at various stages/forums.

(v) There are no bank and corporate guarantee given by the company.

Note 45: Corresponding figures for the previous year presented have been regrouped / rearranged wherever necessary to conform to the current year presentation.

For Anbarasu and Jalapathi

Chartered Accountants

Firm Registration No.: 010795S

(sd.) CA. K. Jalapathi

Partner

Membership no: 214823

For and on behalf of the Board of Directors of

Lotus Eye Hospital and Institute Limited

(sd.) Ms. S.Sangeetha Sundaramoorthy (sd.) CA Perumalsamy Mahendran

Managing Director

DIN: 01859252

Director

DIN:06680557

(sd.) Mr. Senagounder Natesan

Director

DIN: 09012904

(sd.) Dr. K S Ramalingam

Chief Executive Officer,

Executive director

DIN: 01016571

Coimbatore,
May 29, 2025.

(sd.) CA Raghunathan Ramanujam

Chief Financial Officer

(sd.) CS Achuth Menon

Company Secretary

Our Branches



Salem



Saravanampatti




Mulanthuruthy



RS Puram



Sitra, Coimbatore



Tirupur



Mettupalayam



Karur



Kochi, Kerala

Sitra, Coimbatore
770/12, Avinashi Road,
Civil Aerodrome Post, Sitra,
Coimbatore, Tamil Nadu 641 014.
☎ +91 73976 97774

Timings : 7.30am to 7.00pm

Mettupalayam
28, Coimbatore Main Road,
Opp. Bus Stand, Mettupalayam,
Tamil Nadu 641301
☎ +91 73976 47772
Timings : 8.00am to 7.00pm

Salem
86, Brindhavan Road, Fairlands,
Salem, Tamil Nadu 636016
☎ +91 77081 11009

Timings : 9.00am to 8.00pm

Saravanampatti
SF.No: 86/1, Site No: 2 TRM Avenue,
Sathy Road, Saravanampatti,
Coimbatore - 641035.
☎ +91 77081 46600
Timings : 9.00am to 8.00pm

Tiruppur
415,415-1,415-2, Kamaraj Road,
Near Santha Pettai Bus Stop,
Tennampalayam, Palladam Road,
Tiruppur, Tamil Nadu 641 604.
☎ +91 77080 01869
Timings : 9.00am to 8.00pm

Cochin
533/33A - 33F Tejas Tower,
Sahodaran Ayyappan Rd,
Kadavanthra, Kochi, Kerala 682020
☎ +91 99950 34567
Timings : 8.30am to 7.00pm

R.S. Puram, Coimbatore
155B, E Periasamy Rd, Opposite
Chinthamani North, R.S. Puram,
Coimbatore, Tamil Nadu 641 002.
☎ +91 77087 36111

Timings : 9.00am to 7.00pm

Mulanthuruthy
#229-A, Kurisingal Building,
Mulanthuruthy, Ernakulam,
Kerala 682314
☎ +91 81298 88233
Timings : 9.00am to 6.00pm

Karur
28,28/2 sengundhapuram main road,
Karur - 639 002
☎ +91 89259 42758
Timings : 9.00am to 6.00pm

✉ info@lotuseye.org

🌐 www.lotuseye.org
☎ 74485 14851